WO1998010763A1 - Thrombin inhibitors - Google Patents

Thrombin inhibitors Download PDF

Info

Publication number
WO1998010763A1
WO1998010763A1 PCT/US1997/015989 US9715989W WO9810763A1 WO 1998010763 A1 WO1998010763 A1 WO 1998010763A1 US 9715989 W US9715989 W US 9715989W WO 9810763 A1 WO9810763 A1 WO 9810763A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
alkyl
preparation
solution
mammal
Prior art date
Application number
PCT/US1997/015989
Other languages
French (fr)
Inventor
Adel M. Naylor-Olsen
Gerald S. Ponticello
Joseph P. Vacca
Randall W. Hungate
Craig Coburn
Brian T. Phillips
S. D. Lewis
Mark E. Fraley
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9624278.9A external-priority patent/GB9624278D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to CA002264037A priority Critical patent/CA2264037A1/en
Priority to AU44117/97A priority patent/AU725403B2/en
Priority to EP97942415A priority patent/EP0927035A4/en
Priority to JP10513809A priority patent/JP2001500864A/en
Publication of WO1998010763A1 publication Critical patent/WO1998010763A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • Thrombin is a serine protease present in blood plasma in the form of a precursor, prothrombin. Thrombin plays a central role in the mechanism of blood coagulation by converting the solution plasma protein, fibrinogen, into insoluble fibrin.
  • European Publication 363 284 describes analogs of peptidase substrates in which the nitrogen atom of the scissile amide group of the substrate peptide has been replaced by hydrogen or a substituted carbonyl moiety,
  • Australian Publication 86245677 also describes peptidase inhibitors having an activated electrophilic ketone moiety such as fluoromethylene ketone or ⁇ -keto carboxyl derivatives.
  • Thrombin inhibitors described in prior publications contain sidechains of arginine and lysine. These structures show low selectivity for thrombin over other trypsin-like enzymes. Some of them show toxicity of hypotension and liver toxicity.
  • European Publication 601 459 describes sulfonamido heterocyclic thrombin inhibitors, such as N-[4-[(aminoimino- methyl)amino]butyl]-l-[N-(2-naphthalenylsulfonyl)-L-phenylalanyl]-L- prolinamide.
  • WO 94/29336 describes compounds which are useful as thrombin inhibitors.
  • the invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, -and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier.
  • compositions may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents.
  • the compositions can be added to blood, blood products, or mammalian organs in order to effect the desired inhibitions.
  • the invention also includes a composition for preventing or treating unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels, in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier.
  • These compositions may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents.
  • the invention also includes die use of a compound of the invention in the manufacture of a medicament for preventing or treating unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanahzed vessels, in a mammal.
  • the invention also includes a method for reducing the thrombogenicity of a surface in a mammal by attaching to the surface, either covalently or noncovalently, a compound of the invention.
  • R 1 , R2, and R4 are independently selected from hydrogen, aryl, -CO2R 5 , aryl Cl-4 alkyl, diary 1 Cl-4 aikyl, dicyclo C3-8 alkyl Cl-4 alkyl, cyclo C3-8 alkyl Cl-4 alkyl,
  • R5 and R6 are independently hydrogen or Cl -4 alkyl, substituted aryl with one or two substituents selected from Cl-4 alkyl, Ci -4 alkoxy,
  • R wherein R5 and R6 are independently hydrogen or Cl-4 alkyl, aryloxy, cyclo C3-8 alkoxy, methylenedioxy, halogen, or hydroxy, heteroaryl with one or two heteroatoms selected from N,
  • R3 is hydrogen
  • R ⁇ is hydrogen or Cl-4 alkyl
  • A is selected from one of the following fragments
  • J is (CH2)m, (CH2)mNH, or S02, where m is 1 or 2;
  • R 1 and R ⁇ are independently selected from hydrogen, aryl, or cyclo C3-7 alkyl unsubstituted or substituted with one or more of Cl-4 alkyl, Cl-4 alkoxy, benzyl, cyclohexylmethyl or aryl;
  • R3 is hydrogen, C l -4 alkyl, or Cl-4 alkenyl
  • A is selected from one of the following fragments
  • R 1 and R ⁇ are independently selected from hydrogen, aryl, or cyclohexyl
  • A is selected from one of the following fragments
  • Designation BOC (Boc) t-butyloxycarbonyl HBT(HOBT or HOBt) 1 -hydroxybenzotriazole hydrate BBC reagent benzotriazolyloxy-bis(pyrrolidino)- carbonium hexafluorophosphate
  • the compounds of the present invention may have chiral centers and occur as racemates, racemic mixtures and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention.
  • alkyl is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having 1-8 carbon atoms (Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl).
  • Alkenyl is intended to include both branched- and straight-chain unsaturated aliphatic hydrocarbon groups having 1 -8 carbon atoms, e.g. ethenyl, propenyl, etc.
  • Cycloalkyl includes cyclic saturated aliphatic hydrocarbon groups having 3-8 carbon atoms.
  • Aryl means a 6-membered organic radical derived from an aromatic hydrocarbon by removal of one hydrogen atom.
  • Heteroaryl means a 5- or 6- membered organic radical having 1 or 2 heteroatoms selected from N, O, and S.
  • Alkoxy represents an alkyl group having 1-8 carbon atoms attached through an oxygen bridge.
  • Halo as used herein, means fluoro, chloro, bromo and iodo.
  • Counterrion is used to represent a small, single negatively-charged species, such as chloride, bromide, hydroxide, acetate, trifluroacetate, perchlorate, nitrate, benzoate, maleate, tartrate, hemitartrate, benzene sulfonate, and the like.
  • heterocycle or heterocychc represents a stable 5- to 7-membered mono- or bicyclic or stable 7- to 10-membered bicyclic heterocychc ring system any ring of which may be saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocychc rings is fused to a benzene ring.
  • the heterocychc ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heterocychc elements examples include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimid
  • the pharmaceutically-acceptable salts of the compounds of Formula I include the conventional non-toxic salts or the quaternary ammonium salts which are formed, e.g., from inorganic or organic acids or bases.
  • acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tos
  • Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D- glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides
  • dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates
  • long chain halides such as decyl, lauryl, myristyl and stearyl
  • Amide couplings used to form the compounds of this invention are typically performed by the carbodiimide method with reagents such as dicyclohexylcarbodiimide, or l-ethyl-3-(3- dimethylaminopropyl) carbodiimide.
  • reagents such as dicyclohexylcarbodiimide, or l-ethyl-3-(3- dimethylaminopropyl) carbodiimide.
  • Other methods of forming the amide or peptide bond include, but are not limited to the synthetic routes via an acid chloride, azide, mixed anhydride or activated ester.
  • solution phase amide coupling are performed, but solid-phase synthesis by classical Merrifield techniques may be employed instead. The addition and removal of one or more protecting groups is also typical practice.
  • a general method for synthesizing compounds found in tables 2 and 3 is outlined Scheme II.
  • a benzoic acid such as II- 1 (obtained in standard fashion) is coupled to 4-amino-pyridine under standard amide bond coupling conditions.
  • the resultant amide LI-2 is then reduced with lithium aluminum anhydride to afford the desired product II-3.
  • a general method for synthesizing compounds found in table 2 is outlined Schemes II and HI.
  • a benzoate ester such as EH-4 obtained in standard fashion
  • an alkylating reagent such as bromomethyl cyclohexane
  • the ester is hydrolyzed with an aqueous base and is coupled to 4- aminopyridine under standard amide bond coupling conditions.
  • the resultant amide III-7 is men reduced with lithium aluminum hydride to afford the desired product III-8.
  • a method for preparing compounds found in table 4 is outlined in Scheme V.
  • Substituted benzene compound such as 4- benzyloxy-benzene (V-1) is reacted with sulfuryl chloride at 80-120°C to give a sulfonyl chloride.
  • the sulfonyl chloride (V-2) is reacted with Boc-piperazine and the Boc protecting group is removed with a strong acid to afford the deprotected piperazine.
  • the free nitrogen is converted to the amidine with a guanylating reagent such as amidinosulfonic acid.
  • a general method for synthesizing compounds found in table 5 is outlined in Scheme VI.
  • the ketone of a cyano-benzophenone such as 1 is reduced with a metal hydride reagent such as sodium borohydride and the resultant alcohol is removed by treatment with dimethyldichlorosilane to afford the diphenylmethane VI-3.
  • the methoxy group is removed with borontribromide and the phenol is alkylated with an alkylating reagent such as benzyl bromide.
  • the cyano group is then treated with sodium hexamethyldisilazane and the silylimidate is hydrolyzed with an acidic workup to afford the final product.
  • Step A Preparation of ethyl 4-( 1 , 1 -diphenylmethoxy)benzoate
  • Step B Preparation of 4— (1,1 -dipheny lmethoxy)benzy 1 alcohol
  • Step C Preparation of 4-( 1 , 1 -diphenylmethoxy)benzyl bromide
  • Step A Preparation of l .l-dicvclohexyl-2-hvdroxy ethane (5-2)
  • Step B Preparation of ethyl 4-( 1 , 1 -dicyclohexy l)ethoxybenzoate
  • Step D Preparation of 4-amino-l-[4-(2,2-diphenyl-ethoxy> benzyllpyridinium bromide (7-7)
  • Step D Preparation of 4-amino- 1 -[4-(dicyclohexylmethoxy)- benzyllpyridinium bromide (8-7)
  • Oxalyl chloride (3.3 g, 26 mmol) was added under N2 dropwise to a suspension of 10-1 (5.0 g, 22 mmol) in CH2CI2 (75 ml) with 4 drops of DMF. After 1 h the solution was concentrated to dryness and flushed once with CHCI3. The residue was dissolved in CHCI3 (60 ml) and added dropwise to a suspension of 4-AP (6.2 g, 66 mmol) in CHCI3 (100 ml). After 1 h at room temperature the solution was poured into saturated Na2C ⁇ 3 and separated. The aqueous was further extracted with EtOAc (3x). The combined extracts were dried, filtered and concentrated to dryness. The residue was chromatographed on a Still column (80 mm) and the product eluted with 10% CH3OH- CHCI3 to yield 10-2.
  • Step A Preparation of l -phenyl-2-methyl-l-propanol (13-2)
  • Isobutyrophenone 13-1 (29.6 g, 0.20 mmol) was dissolved in ethanol (300 ml) and was reduced under N2 with sodium borohydride (7.57 g, 0.20 mmol) for 4 hrs. at room temperature. The ethanol was removed in vacuo and the residue was taken up in ethyl acetate (200 ml) and water (100 ml). The ethyl acetate extract was washed with water, dried, filtered and concentrated in vacuo to obtain alcohol 13-2.
  • Step B Preparation of ethyl 4-(2-methyl-l-phenyl- propoxy)benzoate (13-5)
  • Step D Preparation of 4-(2-methyl-l-phenylpropoxy)benzoyl chloride (13-7)
  • StepJE Preparation of 4-(2-methyI-l-phenyl ⁇ ropoxy)-N-(4- pyridyDbenzamide (13-9)
  • Step F Preparation of 4-[4-(2-methyl-l -phenylpropoxy)- benzylaminolpyridine (13-10)
  • Step A Preparation of ethyl 4-(2.2-diphenylethoxy)benzoate (14-3)
  • Step C Preparation of 4-(2,2-diphenylethoxy)-N-(4-pyridyl)benz- amide (14-6)
  • Step D Preparation of 4-[4-(2,2-diphenylethoxy)benzyl- aminolpyridine (14-7)
  • This amide was prepared from 15-5 (0.53 g, 2 mmol) and 4-aminopyridine (15-6) (0.188 g, 2 mmol) as in Example 13.
  • the solid obtained, 15-7. melted at 123-125°C. iH NMR (d6-DMSO) ⁇ 0.88-1.03 (2H, m), 1.05-1.3 (3H, m), 1.4-1.56 (IH, m), 1.56-1.8 (7H, m), 4.1 (2H, t), 7.08 (2H, d), 7.78 (2H, d), 7.95 (2H, d), 8.45 (2H, d), 10.42 (IH, s).
  • Step D Preparation of 4-(4-dicyclohexylmethoxy)-N-(4- pyridvDbenzamide (16-7)
  • Step A Preparation of 1.3-diphenyl-2-propanol (17-2)
  • Step B Preparation of ethyl 4-(l ,3-diphenyI-2-propoxy)benzoate
  • Step E Preparation of 4-(l ,3-diphenyl-2-propoxy)-N-(4- pyridyPbenzamide (17-8)
  • 4-Aminopyridine 17-7 (0.471 g, 5 mmol) was acylated with 7-6 (1.75 g, 5 mmol) using the conditions of Example 13.
  • the amide 7-8 was obtained as a solid foam.
  • Step F Preparation of 4-[4-(l,3-diphenyI-2-propoxy)-benzyl- aminolpyridine (17-9)
  • Step A Preparation of ethyl 4-(3,4-methylenedioxybenzyl- oxy)benzoate (1 -3)
  • Step B Preparation of ethyl 4-(3,4-methylenedioxybenzyl- oxy)benzoic acid (18-4)
  • Step C Preparation of 4-(3,4-methylenedioxybenzyloxy)-N-(4- pyridyDbenzamide (18-6)
  • Step D Preparation of 4-[4-(3,4-methylenedioxybenzyl- oxy)benzylamino1pyridine (18-7)
  • Benzyl bromide (0.216 mL, 1.81 mmol, 1.2 equiv) was added to a suspension of 20-2 (400 mg, 1.51 mmol, 1 equiv) and cesium carbonate (1.72 g, 5.30 mmol, 3.5 equiv) in N, N-dimethylformamide (15 mL) at 23°C.
  • the reaction mixture was heated to 70°C and was stirred at that temperature for 2h.
  • the solution was cooled to 23°C and was concentrated.
  • the residue was diluted with ethyl acetate (60 mL), and the resulting solution was washed with an aqueous saturated ammonium chloride solution (2 x 30 mL).
  • Oxalyl chloride (0.391 mL, 4.49 mmol, 3 equiv) was added to a solution of 20-4 (509 mg, 1.49 mmol, 1 equiv) in dichloromethane (6 mL) at 23°C. Once gas evolution ceased (approximately 5 min after the addition of oxalyl chloride), the volatiles were removed in vacuo.
  • a solution of lithium aluminum hydride in tetrahydrofuran (1.0 M, 4.12 mL, 4.12 mmol, 4 equiv) was added to a solution- of 20-5 (430 mg, 1.03 mmol, 1 equiv) in tetrahydrofuran (3 mL) at 0°C.
  • the reaction mixture was heated to 50°C and held at that temperature for 2 h.
  • the mixture was cooled to 0°C, and excess lithium aluminum hydride was quenched by the consecutive addition of water (0.155 mL), aqueous 15% sodium hydroxide solution (0.155 mL), and water (0.467 mL).
  • the resulting aluminum salts were removed by filtration.
  • StepJD Preparation of N-(4-pyridyl)-3-amino-4-(cyclohexyI- methyloxy)benzamide (21-5)
  • Step E Preparation of 4- ⁇ [3-amino-4-(cyclohexylmethyl- oxy)phenv ⁇ methylamino)pyridine dihydrochloride (21 -6)
  • Step F Preparation of 4- [ [3-emylammo-4-(cyclohexylmethyl- oxy)phenyllmethylaminolpyridine dihvdrochloride (21 -7c)
  • Step 1 To a mixture of V-(4-pyridyl)-3-amino-4-(cyclohexyl- methyloxy)benzamide (21 -7a) (0.065 g, 0.20 mmol) in methylene chloride (1 ml) under nitrogen cooled in ice-bath was added acetic anhydride (0.040 ml, 0.42 mmol). The resulting mixture was stirred with ice-bath cooling for 2 h.
  • Step 2 Employing the procedure substantially as described for the preparation of 21-6. but starting with 21 -7b (0.055g, 0.15 mmol), 21 -7c was obtained as a white solid, mp: 137-145°C.
  • dH(DMSO-d6) 9.16 (IH, bs), 8.22 (IH, m), 8.13 (IH, m), 6.95-7.15 (3H, m), 6.97 (IH, d, 77 Hz), 6.87 (IH, d, 7 7 Hz), 4.45 (2H, d, 7 5 Hz), 3.83 (2H, d, 7 5 Hz), 3.4-3.8 (2H, br s), 3.18 (2H, q, 77 Hz), 1.60- 1.90
  • Step G 4- ⁇ [3-(phenylmethylsulfonamido)-4-(cyclohexylmethy 1- oxy)phenvnmethylamino)pyridine dihvdrochloride (21 -7e) Step 1: To a mixture of 21 -7a (0.065 g, 0.20 mmol) and pyridine
  • Step 2 Employing the procedure substantially as described for the preparation of 21-6. but starting with 21-7d (0.077 g, 0.16 mmol), 2 ⁇ 7e, was obtained as a white solid, mp: 135-140°C.
  • dH(DMSO-d6) 9.07 (IH, bs), 8.79 (IH, bs), 8.17 (2H, d, 7 6 Hz), 7.26- 7.35 (5H, m), 7.19 (IH, d, 7 2 Hz),7.12 (IH, d, 7 8 Hz), 7.03 (IH, d, 7 8 Hz), 6.92 (2H, bs), 4.43 (4H, m), 3.80 (2H, d, 7 6 Hz), 1.62-1.82 (6H, m), 1.12-1.30 (3H, m), 0.95-1.10 (2H, m). Analysis calculated for C26H31 N303S»HC1:
  • Step F Preparation of iV-(4-pyridyl)-3-propyl-4-(cyclohexyl- methyloxy)benzamide (22-7)
  • Step G Preparation of 4- ⁇ [3-propyl-4-(cyclohexylmethyl- oxy)phenyllmethylamino ) pyridine (22-8)
  • Step F Preparation of V-(4-pyridyl)-3-ethyl-4-(cyclohexyl- methyloxy)benzamide (23-7)
  • Step G Preparation of 4- ⁇ [3-ethyl-4-(cyclohexylmethyl- oxy)phenvnmethylamino Ipyridine (23-8)
  • Step B Preparation of N-((4-benzyloxy)phenylsulfonyI)-N'-t- Butyloxycarbonylpiperazine (24-3) -
  • Step C Preparation of N-((4-benzyloxy)phenylsuIfonyl)- piperazine (24-4)
  • Step D Preparation of N-((4-benzyloxy)phenylsulfonyI)-N' aminomethyliminopiperazine (24-5)
  • 25-1 was synthesized in the same manner as 24-5 by substituting 4-cyclohexylmethyloxy-3-ethylbenzene for 4- benzyloxybenzene in Step A, Example 24 .
  • Step D Preparation of 4- ⁇ [4-(Phenylmethyloxy)phenyl]- methyllbenzonitrile (26-5)
  • Step E Preparation of 4- ⁇ [4-(Phenylmethyloxy)phenyl]- methy 11 benzamidine hydrochloride (26-6)
  • Step A Preparation of 4- ⁇ [4-(Cyclohexylmethyloxy)phenyl]- ethyUbenzonitrile (27-1)
  • Step B Preparation of 4- ⁇ [4-(Cyclohexylmethyloxy)phenyl]- methvDbenzamidine hydrochloride (27-3)
  • Step D Preparation of N-( 4-phenoxymethylbenzyl)amino- pyridine (28-6)
  • Step B Preparation of ethyl 3-cyclohexylmethyloxy-phenylacetate (29-3)
  • Step C Preparation of 3-cyclohexylmethyloxy-phenylacetic acid (29-4) '
  • a solution of aqueous sodium hydroxide (IN, 14 mL, 14.0 mmol, 10 equiv) was added to a solution of ethyl 3-cyclohexyl- methyloxy-phenylacetate 29-3 (384 mg, 1.39 mmol, 1 equiv) in a mixture of t-butanol (8 mL) and water (4 mL) at 23 °C.
  • the reaction mixture was heated at reflux for 2h.
  • the solution was cooled to 23°C and was diluted with ethyl acetate (50 mL).
  • Step D Preparation of N-4'-pyridyl-(3-cyclohexylmethyl- oxy)phenylacetamide (29-5)
  • Oxalyl chloride (0.158 mL, 1.81 mmol, 3 equiv) and a catalytic amount of N, N-dimethylformamide (2 mL) were added consecutively to a solution of 29-4 (150 mg, 0.604 mmol, 1 equiv) in dichloromethane (2 mL) at 23°C. Once gas evolution ceased (approximately 2 min following the addition of the N, N- dimethylformamide), the volatiles were removed in vacuo.
  • Step E Preparation of 4-(2-(3-cyclohexylmethyIoxy- phenvDethyDaminopyridine (29-6)
  • Concentrations of stock solutions of Z-GPR-afc were determined from measurements of absorbance at 380 nm of the 7- amino-4-trifluoromethylcoumarin produced upon complete hydrolysis of an aliquot of the stock solution by thrombin.
  • Activity assays were performed by diluting a stock solution of substrate at least tenfold to a final concentration 0.5 Km into a solution containing enzyme or enzyme equilibrated with inhibitor. Times required to achieve equilibration between enzyme and inhibitor were determined in control experiments. Initial velocities of product formation in the absence (Vo) or presence of inhibitor (Vi) were measured.
  • the activities shown by this assay indicate that the compounds of the invention are therapeutically useful for treating various conditions in patients suffering from unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, and reocclusion or restenosis of recanahzed vessels.
  • Anticoagulant therapy is indicated for the treatment and prevention of a variety of thrombotic conditions, particularly coronary artery and cerebrovascular disease. Those experienced in this field are readily aware of the circumstances requiring anticoagulant therapy.
  • patient used herein is taken to mean mammals such as primates, including humans, sheep, horses, cattle, pigs, dogs, cats, rats, and mice.
  • thrombin inhibition is useful not only in the anticoagulant therapy of individuals having thrombotic conditions, but is useful whenever inhibition of blood coagulation is required such as to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage.
  • thrombin inhibitors can be added to or contacted with any medium containing or suspected of containing thrombin and in which it is desired that blood coagulation be inhibited, e.g., when contacting the mammal's blood with material selected from the group consisting of vascular grafts, stents, orthopedic prothesis, cardiac prosthesis, and extracorporeal circulation systems
  • the thrombin inhibitors of the invention can be administered in such oral forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixers, tinctures, suspensions, syrups, and emulsions. Likewise, they may be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an anti -aggregation agent. For treating ocular build up of fibrin, the compounds may be administered intraocularly or topically as well as orally or parenterally.
  • the thrombin inhibitors can be administered in the form of a depot injection or implant preparation which may be formulated in such a manner as to permit a sustained release of the active ingredient.
  • the active ingredient can be compressed into pellets or small cylinders and implanted subcutaneously or intramuscularly as depot injections or implants.
  • Implants may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or . other polymers manufactured by the Dow-Coming Corporation.
  • the thrombin inhibitors can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
  • the thrombin inhibitors may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • the thrombin inhibitors may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include polyvinlypyrrolidone, pyran copolymer, polyhydroxy-propyl- methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.
  • the thrombin inhibitors may be coupled to a class of biodegradable polymers useful in achieving controlled release of a dmg, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
  • biodegradable polymers useful in achieving controlled release of a dmg, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
  • the dosage regimen utilizing the thrombin inhibitors is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed.
  • An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the dmg required to prevent, counter, or arrest the progress of the condition.
  • Oral dosages of the thrombin inhibitors when used for the indicated effects, will range between about 0.1 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day and preferably 1.0- 100 mg/kg/day and most preferably 1-20 mg/kg/day. Intravenously, the most preferred doses will range from about 0.01 to about 10 mg/kg/minute during a constant rate infusion.
  • the thrombin inhibitors may be administered in divided doses of two, three, or four times daily. Furthermore, they can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art.
  • oral tablets can be prepared which contain an amount of active compound of between 100 and 500 mg, typically between 200 and 250 mg.
  • a patient in need of thrombin inhibitor compound depending on weight and metabolism of the patient, would be administered between about 100 and 1000 mg active compound per day.
  • two tablets containing 250 mg of active compound can be administered in the morning and two tablets containing 250 mg of active compound can again be administered in the evening.
  • one tablet containing 250 mg of active compound can be administered in the morning and one tablet containing 250 mg of active compound can again be administered in the evening.
  • thrombin inhibitors are typically administered as active ingredients in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier” materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixers, symps and the like, and consistent with convention pharmaceutical practices.
  • carrier suitable pharmaceutical diluents, excipients or carriers
  • the active dmg component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral dmg components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture.
  • suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture.
  • Suitable binders include starch, gelatin, natural sugars such as glucose or beta- lactose, com-sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch methyl cellulose, agar, bentonite, xanthan gum and the like.
  • the thrombin inhibitors can also be co-administered with suitable anti-coagulation agents or thrombolytic agents such as plasminogen activators or streptokinase to achieve synergistic effects in the treatment of various ascular pathologies.
  • suitable anti-coagulation agents or thrombolytic agents such as plasminogen activators or streptokinase to achieve synergistic effects in the treatment of various ascular pathologies.
  • thrombin inhibitors enhance the efficiency of tissue plasminogen activator- mediated thrombolytic reperfusion.
  • Thrombin inhibitors may be administered first following thrombus formation, and tissue plasminogen activator or other plasminogen activator is administered thereafter. They may also be combined with heparin, aspirin, or warfarin.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A compound which inhibits human thrombin and which has general structure (I) such as formula (a).

Description

TITLE OF THE INVENTION THROMBIN INHIBITORS
BACKGROUND OF THE INVENTION
Thrombin is a serine protease present in blood plasma in the form of a precursor, prothrombin. Thrombin plays a central role in the mechanism of blood coagulation by converting the solution plasma protein, fibrinogen, into insoluble fibrin.
Edwards et al., J. Amer. Chem. Soc, (1992) vol. 1 14, pp. 1854-63, describes peptidyl a-ketobenzoxazoles which are reversible inhibitors of the serine proteases human leukocyte elastase and porcine pancreatic elastase.
European Publication 363 284 describes analogs of peptidase substrates in which the nitrogen atom of the scissile amide group of the substrate peptide has been replaced by hydrogen or a substituted carbonyl moiety,
Australian Publication 86245677 also describes peptidase inhibitors having an activated electrophilic ketone moiety such as fluoromethylene ketone or α-keto carboxyl derivatives.
Thrombin inhibitors described in prior publications contain sidechains of arginine and lysine. These structures show low selectivity for thrombin over other trypsin-like enzymes. Some of them show toxicity of hypotension and liver toxicity.
European Publication 601 459 describes sulfonamido heterocyclic thrombin inhibitors, such as N-[4-[(aminoimino- methyl)amino]butyl]-l-[N-(2-naphthalenylsulfonyl)-L-phenylalanyl]-L- prolinamide.
WO 94/29336 describes compounds which are useful as thrombin inhibitors. SUMMARY OF THE INVENTION
A compound which inhibits human thrombin and which has the general structure
Figure imgf000004_0001
such as
Figure imgf000004_0002
The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, -and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. These compositions may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents. The compositions can be added to blood, blood products, or mammalian organs in order to effect the desired inhibitions.
The invention also includes a composition for preventing or treating unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels, in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. These compositions may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents.
The invention also includes die use of a compound of the invention in the manufacture of a medicament for preventing or treating unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanahzed vessels, in a mammal.
The invention also includes a method for reducing the thrombogenicity of a surface in a mammal by attaching to the surface, either covalently or noncovalently, a compound of the invention.
DETAILED DESCRIPTION OF THE INVENTION
Compounds of the invention have the following structure:
Figure imgf000005_0001
I
and pharmaceutically acceptable salts thereof wherein
X is
-N(R4)-,
-0-,
-S-,
-S02-,
-SO-,
-OCH2(CH2)n aryl-, or
-OCH2(CH2)n C3-8cycloalkyl-, wherein n is 1 or 2; J is
-(CH2)m-,
-(CH2)mNH-,
-SO2NH-,
-Sθ2(CH2)m-, -NHSO2-, -S02-, or -(CH2)mS02-, wherein m is 1 or 2;
R 1 , R2, and R4 are independently selected from hydrogen, aryl, -CO2R5, aryl Cl-4 alkyl, diary 1 Cl-4 aikyl, dicyclo C3-8 alkyl Cl-4 alkyl, cyclo C3-8 alkyl Cl-4 alkyl,
Figure imgf000006_0001
, wherein R5 and R6 are independently hydrogen or Cl -4 alkyl, substituted aryl with one or two substituents selected from Cl-4 alkyl, Ci -4 alkoxy,
R5 CONN
R , wherein R5 and R6 are independently hydrogen or Cl-4 alkyl, aryloxy, cyclo C3-8 alkoxy, methylenedioxy, halogen, or hydroxy, heteroaryl with one or two heteroatoms selected from N,
O, and S, cyclo C3-7 alkyl unsubstituted or substituted with one or more of Cl-4 alkyl, Cl-4 alkoxy, benzyl, cyclohexylmethyl or aryl, a C4-10 carbocyclic or bicyclic ring, or
Ri and R^ along with the carbon to which they attach form a cyclo C3- 7 alkyl ring;
R3 is hydrogen,
Cl-4 alkyl,
Cl-4 alkenyl,
Cl-4 alkoxy,
-NHR7 wherein R^ is hydrogen or Cl-4 alkyl, or
-NHS02CH2aryl;
A is selected from one of the following fragments
Figure imgf000007_0001
, wherein B is N or CH.
Figure imgf000007_0002
One group of compounds of the invention have the following structure:
Figure imgf000007_0003
and pharmaceutically acceptable salts thereof wherein
J is (CH2)m, (CH2)mNH, or S02, where m is 1 or 2;
R 1 and R^ are independently selected from hydrogen, aryl, or cyclo C3-7 alkyl unsubstituted or substituted with one or more of Cl-4 alkyl, Cl-4 alkoxy, benzyl, cyclohexylmethyl or aryl;
R3 is hydrogen, C l -4 alkyl, or Cl-4 alkenyl;
A is selected from one of the following fragments
Figure imgf000008_0001
Figure imgf000008_0002
, wherein B is N or CH.
One class of this group of compounds has the following structure:
Figure imgf000008_0003
I and pharmaceutically acceptable salts thereof wherein
J i CH2, CH2NH, or S02;
R 1 and R^ are independently selected from hydrogen, aryl, or cyclohexyl;
R3 is hydrogen, -CH=CH2, or -CH2CH3; and
A is selected from one of the following fragments
Figure imgf000009_0001
Specific exemplifications of this class are
Figure imgf000009_0002
Figure imgf000009_0003
Figure imgf000009_0004
Figure imgf000010_0001
Figure imgf000010_0002
Figure imgf000010_0003
and pharmaceutically acceptable salts thereof.
ABBREVIATIONS
Designation BOC (Boc) t-butyloxycarbonyl HBT(HOBT or HOBt) 1 -hydroxybenzotriazole hydrate BBC reagent benzotriazolyloxy-bis(pyrrolidino)- carbonium hexafluorophosphate
PyCIU 1 ,1 ,3,3-bis(tetramethylene)- chlorouronium hexafluorophosphate
EDC l -ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
(BOC)2θ di-t-butyl dicarbonate DMF dimethylformamide
Et3N or TEA triethylamine EtOAc ethyl acetate
TFA trifluoroacetic acid
DMAP dimethylaminopyridine
DME dimethoxyethane
BH3-THF Borane-tetrahydrofuran complex
D-Phe(3,4-Cl2) D-3 ,4-Dichlorophenylalanine
D-3,3-dicha D-3,3-Dicyclohexylalanine
Pro Proline
Arg Arginine
Gly Glycine
D-3,3,-diphe D-3,3-Diphenylalanine
The compounds of the present invention may have chiral centers and occur as racemates, racemic mixtures and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention.
When any variable occurs more than one time in any constituent or in formula I, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
As used herein, except where noted, "alkyl" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having 1-8 carbon atoms (Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl). "Alkenyl" is intended to include both branched- and straight-chain unsaturated aliphatic hydrocarbon groups having 1 -8 carbon atoms, e.g. ethenyl, propenyl, etc. "Cycloalkyl" includes cyclic saturated aliphatic hydrocarbon groups having 3-8 carbon atoms. "Aryl" means a 6-membered organic radical derived from an aromatic hydrocarbon by removal of one hydrogen atom. "Heteroaryl" means a 5- or 6- membered organic radical having 1 or 2 heteroatoms selected from N, O, and S. "Alkoxy" represents an alkyl group having 1-8 carbon atoms attached through an oxygen bridge. "Halo", as used herein, means fluoro, chloro, bromo and iodo. "Counterion" is used to represent a small, single negatively-charged species, such as chloride, bromide, hydroxide, acetate, trifluroacetate, perchlorate, nitrate, benzoate, maleate, tartrate, hemitartrate, benzene sulfonate, and the like.
Under standard nonmenclature used throughout this disclosure unless specified otherwise, the terminal portion of the designated side chain is described first followed by the adjacent functionality toward the point of attachment. For example, an ethyl substituent substituted with "methylcarbonylamino" is equivalent to
H O
I II
-CH2CH2-N-C-CH3
The term heterocycle or heterocychc, as used herein except where noted, represents a stable 5- to 7-membered mono- or bicyclic or stable 7- to 10-membered bicyclic heterocychc ring system any ring of which may be saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocychc rings is fused to a benzene ring. The heterocychc ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocychc elements include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazoyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl. Morpholino is the same as morpholinyl.
The pharmaceutically-acceptable salts of the compounds of Formula I (in the form of water- or oil-soluble or dispersible products) include the conventional non-toxic salts or the quaternary ammonium salts which are formed, e.g., from inorganic or organic acids or bases. Examples of such acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D- glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.
Amide couplings used to form the compounds of this invention are typically performed by the carbodiimide method with reagents such as dicyclohexylcarbodiimide, or l-ethyl-3-(3- dimethylaminopropyl) carbodiimide. Other methods of forming the amide or peptide bond include, but are not limited to the synthetic routes via an acid chloride, azide, mixed anhydride or activated ester. Typically, solution phase amide coupling are performed, but solid-phase synthesis by classical Merrifield techniques may be employed instead. The addition and removal of one or more protecting groups is also typical practice.
Compounds of the invention can be prepared according to the general procedures outlined in Schemes I-VI.
Compounds found in table 1 were synthesized by the general method outlined in Scheme I and are exemplified by, but not limited to the examples 1-9. A phenolic ester such as ethyl 4- hydroxybenzoic acid (1 ) is alkylated with an alkyl bromide such as benzyl bromide by using a base such as cesium carbonate to afford the product 1-3. The ester group is then reduced with a hydride reducing agent such as lithium aluminum hydride to afford the benzylic alcohol I- 4. The benzylic alcohol is converted into a leaving group (such as a bromide or triflate) and the benzylic leaving group is reacted with 4- aminopyridine to afford the final product.
SCHEMEI
Figure imgf000015_0001
1-1 I-2 I-3
e
Figure imgf000015_0002
A general method for synthesizing compounds found in tables 2 and 3 is outlined Scheme II. A benzoic acid such as II- 1 (obtained in standard fashion) is coupled to 4-amino-pyridine under standard amide bond coupling conditions. The resultant amide LI-2 is then reduced with lithium aluminum anhydride to afford the desired product II-3.
SCHEME π
Figure imgf000016_0001
UAIH4/THF 60°
Figure imgf000016_0002
A general method for synthesizing compounds found in table 2 is outlined Schemes II and HI. A benzoate ester such as EH-4 (obtained in standard fashion) is reacted with an alkylating reagent (such as bromomethyl cyclohexane) to afford O-alkylated product III-5. The ester is hydrolyzed with an aqueous base and is coupled to 4- aminopyridine under standard amide bond coupling conditions. The resultant amide III-7 is men reduced with lithium aluminum hydride to afford the desired product III-8.
SCHEME m
Figure imgf000018_0001
111-1 III-2
Figure imgf000018_0003
Figure imgf000018_0004
III-5 SCHEME m (CONTINUED)
Figure imgf000019_0001
Figure imgf000019_0002
Figure imgf000019_0003
SCHEME IV
Figure imgf000020_0001
IV-1 IV-2
Figure imgf000020_0002
IV-3
Pd(PPh3)4 / dioxane ^SnBu3 COOCH3
IV-4
SCHEME IV (CONTINUED)
Figure imgf000021_0001
IV-5
Figure imgf000021_0002
Figure imgf000021_0003
Figure imgf000021_0004
A method for preparing compounds found in table 4 is outlined in Scheme V. Substituted benzene compound such as 4- benzyloxy-benzene (V-1) is reacted with sulfuryl chloride at 80-120°C to give a sulfonyl chloride. The sulfonyl chloride (V-2) is reacted with Boc-piperazine and the Boc protecting group is removed with a strong acid to afford the deprotected piperazine. The free nitrogen is converted to the amidine with a guanylating reagent such as amidinosulfonic acid.
SCHEME V
Figure imgf000023_0001
A general method for synthesizing compounds found in table 5 is outlined in Scheme VI. The ketone of a cyano-benzophenone such as 1 is reduced with a metal hydride reagent such as sodium borohydride and the resultant alcohol is removed by treatment with dimethyldichlorosilane to afford the diphenylmethane VI-3. The methoxy group is removed with borontribromide and the phenol is alkylated with an alkylating reagent such as benzyl bromide. The cyano group is then treated with sodium hexamethyldisilazane and the silylimidate is hydrolyzed with an acidic workup to afford the final product.
SCHEME VI
Figure imgf000025_0001
Unless otherwise shown, NMR data for the compounds identified below was obtained using a field strength of 400 MHz. Preparation of compounds found in Table I
EXAMPLE
Preparation of 4-amino-l-(4-(l,l-diρhenylmethoxy)benzylpyridinium bromide (1-6)
Figure imgf000026_0001
1 -1 1 -2 1 -3
Figure imgf000026_0002
Step A: Preparation of ethyl 4-( 1 , 1 -diphenylmethoxy)benzoate
(1-3^
Under N2, a mixture of ethyl 4-hydroxybenzoic acid (2.5 g, 15 mmol) , and Cs2Cθ3 (5.0 g, 15 mmol) in DMF (50 ml) was stirred at room temperature. After 15 min, diphenyknethyl bromide 1-2 (4.0 g, 16 mmol) was added and then heated at 60°C. After 18h, saturated Na2C03 was added and the mixture extracted with EtOAc (3x). The combined extracts were washed with H2θ, dried, filtered and concentrated to dryness to yield 1-3. lH NMR (CDC13) δ 1.3 (3H, t), 4.3 (2H, q), 6.95 (2H, s), 7.3 (10H, m) and 7.95 (2H, d).
Step B: Preparation of 4— (1,1 -dipheny lmethoxy)benzy 1 alcohol
(1-4)
To a suspension of LAH (3.2 g, 0.084 mmol) in THF (400 ml) under N2 was added dropwise a solution of _L3_ (21 g, 0.063 mol) in THF (100 ml). After stirring overnight at room temperature, saturated Na2S04 was added to the reaction until a white suspension was observed. The mixture was filtered and the filtrate was combined with H2θ and CHCI3, separated, and extracted further with CHCI3 (2x). The combined organic extracts were dried, filtered and concentrated to dryness. The residue was triturated with hexane to yield 1 -4. lH NMR δ 1.6 (1H, bs), 4.55 (2H, s), 6.2 (1H, s), 6.95 (2H, d), and 7.3 (12H, m).
Step C: Preparation of 4-( 1 , 1 -diphenylmethoxy)benzyl bromide
£JLz5)
A solution of YΛ (3.6 g, 12 mmol), triphenyl phosphine (3.1 g, 1 1.8 mmol) in THF (100 ml) was treated with carbon tetrabromide (3.9 g, 11.8 mmol). After 12h additional triphenylphosphine (3.1 g, 11.8 mmol) was added and the mixture allowed to stir at room temperature overnight. Some triphenyl phosphine oxide was then filtered off and the filtrate concentrated to dryness. The residue was chromatographed on a Still column (70 mm) and the product eluted with 5% EtOAc-hexane to yield 1-5. H NMR (CDC13) δ 4.4 (2H, s), 6.2 (1H, s), 6.9 (2H, d) and 7.35 (12H, m). Step D: Preparation of 4-amino- 1 -(4-( 1 , 1 -diphenyl- methoxy)benzvDpyridium bromide (1-6)
A solution of (0.58 g, 1.6 mmol) in CH3CN (25 ml) was treated under N2 with 4-aminopyridine (0.16 g, 1.7 mmol). After stirring overnight at room temperature, the solid was filtered off to yield 1^6. An analytical sample was crystallized from CH3CN. mp: 254-5°.
Analysis calculated for C25H23BrN2θ
C, 67.12; H, 5.18; N, 6.26 Found: C, 67.25; H, 5.07; N, 6.25 iH NMR (d6-DMSO) δ 5.2 (2H, s), 6.55 (IH, s), 6.8 (2H, d), 7.05 (2H, d), 7.3 (8H, m), 7.47 (4H, d), 8.13 (2H, bs exch) and 8.25 (2H, d).
EXAMPLE 2
Preparation of 4-amino-l-(4-(2-phenyl-l-ethoxy)benzyl)pyridinium bromide (2-2)
2-2 was prepared as described for the preparation of 1-6 except 2-phenyl-l -bromoethane (2-1 ) was used in place of 1-2 in Step A and synthesized, mp: 170-1°C (CH3CN); iH NMR (d6-DMSO) δ 3.0 (2H, t), 4.2 (2H, t), 5.3 (2H, s), 6.82 (2H, d), 6.96 (2H, d), 7.3 (7H, m), 8.15 (2H, exch bs) and 8.27 (2H; d). Analysis calculated for C2θH2lBrN2θ
C, 59.96; H, 5.71; N, 6.99 Found: C, 59.62; H, 5.22; N, 7.14
EXAMPLE 3
Preparation of 4-amino-l -(4-(cyclohexylmethoxy)benzyl)pyridinium bromide (3-3)
3-3 was prepared as described for the synthesis of 1^6 except 4-hydroxy-benzyI alcohol (3-1 ) and cyclohexylmethyl bromide (3-2) were used in Step A to yield 4-(cyclohexylmethoxy)benzyl alcohol directly, mp: 241-3°C; iH NMR (d6-DMSO) δ 1.2 (5H, m), 1.75 (6H, m), 3.8 (2H, d), 5.28 (s, 2H), 6.8 (2H, d), 6.95 (2H, d), 7.34 (2H, d), 8.1 (2H, exch bs), 8.25
(2H, d).
Analysis calculated for Cl 9H25BrN2θ
C, 60.47; H, 6.68; N, 7.42 Found: C, 60.57; H, 6.70; N, 7.15
EXAMPLE 4
Preparation of 4-am o-l-(4-(l -phenyl-l-carbomethoxy)methoxy- benzvDpyridinium bromide (4-2)
4-2 was prepared as described for the synthesis of L^ except methyl 1-bromo-l-phenylacetate (4-1) was used in place of 1-2 in Step A. The compound was crystallized from CH3CN; mp:- 188- 90°C; iH NMR (d6-DMSO) δ 3.65 (3H, s), 5.27 (2H, s), 6.05 (IH, s), 6.83 (2H, d), 7.2 (2H, d), 7.34 (2H, d), 7.42 (3H, m), 7.54 (2H, d), 8.14 (2H, exch bs) and 8.27 (2H, d).
Analysis calculated for C2lH2lBrN2θ«0.25 H2O
C, 58.14; H, 5.00; N, 6.46 Found: C, 57.77; H, 4.94; N, 6.69 EXAMPLE 5
Preparation of 4-amino-l-(4-(2,2-dicycIohexyl-l-ethoxy)benzyl)pyri- dinium bromide (5-5)
Figure imgf000030_0001
Figure imgf000030_0002
Step A: Preparation of l .l-dicvclohexyl-2-hvdroxy ethane (5-2)
A solution of 1,1-dicyclohexylacetic acid (5-1 ) (2.8 g, 12.5 mmol) in THF (5 ml) under N2 was cooled in an ice bath and then 1.0 M borane in THF (17 ml, 17 mmol) was added dropwise. After addition, the solution was stirred at room temperature and then a 1 : 1 mixture of THF/H2O (10 ml) was added carefully. The mixture was added to saturated Na2C03 and extracted with EtOAc (3x). The organic extracts were dried, filtered and concentrated to dryness to yield 5-2. iH NMR (CDC13); δ 1.1 (11H, m), 1.6 (12H, m), 3.65 (2H, d).
Step B: Preparation of ethyl 4-( 1 , 1 -dicyclohexy l)ethoxybenzoate
(5-4
Under N2, 5__2 (1.1 g, 5.2 mmol), ethyl 4-hydroxybenzoate (5-3) (0.9 g, 5.2 mmol), triphenylphosphine (1.6 g, 5.2 mmol), diethyl azodicarboxylate (1.1 g, 6.2 mmol) in THF (15 ml) were placed in a flask and stirred at room temperature. After 2 days, water and Et2θ were added and separated. The aqueous layer was further extracted with Et2θ (2x) and the combined layers backwashed with saturated Na2Cθ3, brine, dried, filtered and concentrated to dryness. The residue was chromatographed on a Still column (40 mm) and the product eluted with 20% EtOAc/hex to yield 5^4.
5-4 was converted to 5^5 as described in Example 1 ; mp: 223-5°C; iH NMR (d6-DMSO) δ 1.4 (23 H, m), 3.93 (2H, s), 5.26 (2H, s), 6.85
(2H, d), 6.95 (2H, d), 7.37 (2H, d), 8.15 (2H, exch bs) and 8.3 (2H, d). Analysis calculated for C26H37N2OBr«0.75 H2O
C, 64.12; H, 7.97; N 5.75 Found: C, 64.25; H, 7.66; N 5.83
EXAMPLE 6
Preparation of 4-amino- 1 -[4-( 1 ,3-diphenyl- 1 -propoxy)benzyl]pyri- dinium bromide (6-8)
Step A: Preparation of 1.3-diphenylpropanol (6-2)
Figure imgf000032_0001
β-Phenylpropiophenone (6-1) (7.5 g, 36.0 mmol) was suspended in ethanol (100 ml) and sodium borohydride (0.68 g, 18.0 mmol) was added under N2. The resulting solution was stirred at ambient temperature overnight. The ethanol was removed in vacuo and the residual oil-solid was taken up in ethyl acetate (100 ml) and water (30 ml). The ethyl acetate layer was removed, washed with water, dried, filtered and concentrated in vacuo to give 6^2 as a colorless oil. iH NMR (d6-DMSO) δ 1.88 (2H, q), 2.6 (2H, m), 4.51 (IH, q), 5.28
(IH, d), 7.1-7.37 (10H, m). Step B: Preparation of ethyl 4-(I ,3-diphenyI-l-propoxy)benzoate
(Ml
Figure imgf000033_0001
COOC2H£
Figure imgf000033_0002
6-4
To 6^2 (2.12 g, 10.0 mmol) in tetrahydrofuran (25 ml) under a nitrogen atmosphere was added ethyl 4-hydroxybenzoate (6-3) (1.66 g, 10.0 mmol) followed by triphenyl phosphine (3.15 g, 12.0 mmol). The mixture was cooled in an ice bath and diethyl azodicarboxylate (2.09 g, 12 mmol) was added. This mixture was stirred overnight at ambient temperature and the solvent was removed in vacuo. The residue was taken up in the water and the ether layer was separated, washed with sodium bicarbonate and water, dried, filtered and concentrated in vacuo to yield an oil. Chromatographic purification on silica gel gave ^4 as a colorless oil. H NMR (d6-DMSO) δ 1.25 (3H, t), 2.1 (IH m), 2.25 (IH, m), 2.66 (IH, m), 2.75 (IH, m), 4.22 (2H, q), 5.4 (IH, t), 6.99 (2H, d), 7.12-7.44 (10H, m), 7.8 (2H, d). Step C: Preparation of 4-( 1 ,3-dipheny 1- 1 -propoxy)benzy 1 alcohol
Figure imgf000034_0001
Figure imgf000034_0002
6-5
A solution of 4 (2.46 g, 6.8 mmol) in ether (30 ml) was added dropwise under nitrogen atmosphere to a stirred cold suspension of lithium aluminum hydride (0.285 g, 7.5 mmol) in ether (5 ml). The mixture was stirred for 3 hrs at ambient temperature and was decomposed by carefully adding water and sodium hydroxide. This mixture was extracted with ethyl acetate. The extract was washed with water, dried, filtered and concentrated in vacuo to yield 6ι5 as a colorless viscious oil. iH NMR (d6-DMSO) δ 2.05 (IH, m), 2.2 (IH, m), 2.66 (IH, m), 2.75 (IH, m), 4.34 (2H, d), 4.99 (IH, t), 5.26 (IH, t), 6.81 (2H, d), 7.04-7.4 (12H, m). Step D: Preparation of 4-(l ,3-diphenyl-l-propoxy)benzyl bromide (6-6)
Figure imgf000035_0001
Figure imgf000035_0002
To an ice cold solution of 6^5 (1.19 g, 6.0 mmol) in acetonitrile (15 ml) was added pyridine (0.76 g, 9.6 mmol) and then triphenylphosphine dibromide (3.29 g, 7.8 mmol). The mixture was stirred at ice bath temperature for 1/4 hr under N2 and at ambient temperature for 1&3/4 hrs and then was filtered. Concentration of the filtrate in vacuo gave a crude oil. The pure product 6^6 was obtained after three silica gel chromatographic separations. iH NMR (d6-DMSO) δ 2.06 (IH, m), 2.2 (IH, m), 2.66 (IH, m), 2.75 (IH, m), 4.62 (2H, s), 5.3 (IH, t), 6.82 (2H, d), 7.16-7.4 (12H, m). Step E: Preparation of 4-amino-l-[4-(l ,3-diphenyl-l-propoxy)- benzyllpyridinium bromide (6-8)
Figure imgf000036_0001
Figure imgf000036_0002
To a solution of 4-(l ,3-diphenyl-l-propoxy)benzyl bromide 5 (0.381 g, 1.0 mmol) in acetonitrile (7 ml) was added 4- aminopyridine (6-7) (94 mg, 1.0 mmol) with stirring at room temperature. The mixture was stirred for 3 hrs and the resulting white suspension was filtered. The white solid obtained 6-8. melted at 215- 216.5°C. Recry stall ization from acetonitrile raised the melting point to 218.5-220°C. iH NMR (d6-DMSO) δ 2.06 (IH, m), 2.2 (IH, m), 2.65 (IH, m), 2.75
(IH, m), 5.2 (2H, s), 5.3 (IH, m), 6.8 (2H, d), 6.9 (2H, d), 7.16-7.41
(12H, m), 8.12 (2H, s), 8.24 (2H, d). Analysis calculated for C27H27N2θBr
C, 68.21 ; H, 5.73; N, 5.89 Found: C, 68.48; H, 5.68; N, 5.98 EXAMPLE 7
Preparation of 4-amino-l-[4-(2,2-diphenylethoxy)benzyl]pyridinium bromide (7-7)
Step A: Preparation of ethyl 4-(2.2-diphenylethoxy)benzoate (7-3)
Figure imgf000037_0001
2,2-Diphenylethanol (7-1) (5.95 g, 30 mmol) and ethyl 4- hydroxybenzoate (7-2) (5.48 g, 30 mmol) were reacted, as in Example 6. 7^3 was obtained after chromatography as a colorless oil. iH NMR (CDCI3): δ 1.36 (3H, t), 4.33 (2H, q), 4.52 (3H, s), 6.9 (2H, d), 7.2-7.36 (10 H, m), 7.96 (2H, d). Step B: Preparation of ethyl 4-(2,2-diphenylethoxy)benzyl alcohol
12=4)
Figure imgf000038_0001
Figure imgf000038_0002
7-3 (0.757 g, 2.2 mmol) was dissolved in ether (20 ml) and was reduced with lithium aluminum hydride (92 mg, 2.4 mmol) under nitrogen as in Example 6, Step B. 2= was obtained as a colorless oil. iH NMR (d6-DMSO) δ 1.55 (IH, t), 4.45-4.52 (3H, m), 4.61 (2H, d), 6.88 (2H, d), 7.2-7.35 (12H, m).
Step C: Preparation of 4-(2.2-diphenylethoxy)benzyl bromide (7-5)
Figure imgf000039_0001
Figure imgf000039_0002
7-4 (0.572 g, 1.9 mmol) was dissolved in ether (10 ml). The solution was cooled in ice and phosphorus tribromide (0.204 g, 0.75 mmol) was added. After 1/2 hr. the reaction was diluted with methanol (2 ml) and water (5 ml). The ether layer was separated, washed with sodium bicarbonate and water, dried and filtered. Concentration of the filtrate in vacuo gave 2=5. as a white solid, mp: 70-73°C. iH NMR (d6-DMSO): δ 4.43-4.62 (3H, m), 4.64 (2H, s), 6.9 (2H, d), 7.15-7.4 (12H, m).
Step D: Preparation of 4-amino-l-[4-(2,2-diphenyl-ethoxy> benzyllpyridinium bromide (7-7)
Figure imgf000040_0001
Figure imgf000040_0002
7-5 (100 mg, 0.27 mmol) was reacted with 4- aminopyridine 2=6 (28 mg, 0.30 mmol) in acetonitrile (3 ml) as in Example 6, Step E. The white solid product 2=2 was obtained, mp: 137-139°C. IH NMR (d6-DMSO) δ: 4.45-4.59 (3H, m), 5.27 (2H, s), 6.82 (2H, d),
6.98 (2H, d), 7.17-7.4 (12H, m), 8.13 (2H, s), 8.27 (2H, d). Analysis calculated for (C26H25N2θBr«0.5 H2θ):
C, 66.38; H, 5.57; N, 5.96 Found: C, 66.57; H, 5.42; N, 5.98 EXAMPLE 8
Preparation of 4-amino-l-[4-(dicyclohexylmethoxy)benzyl]pyridinium bromide (8-7)
Step A: Preparation of ethyl 4-(dicyclohexylmethoxy)benzoate (8-3)
Figure imgf000041_0001
Figure imgf000041_0002
Dicyclohexylmethanol (8-1) (4.91 g, 25 mmol) and ethyl 4- hydroxybenzoate (8-2) (4.15 g, 25 mmol) were reacted, as in Example 6, Step B, to obtain a colorless oil 8^ after chromatography. *H NMR (CDCI3): δ 0.98-1.3 (11H, m), 1.36 (3H, t), 1.58-1.86 (11H, m), 4.02 (IH, t), 4.33 (2H, q), 6.92 (2H, d), 7.94 (2H, d). Step B: Preparation of 4-(dicyclohexylmethoxy)benzyl alcohol
(Ml
Figure imgf000042_0001
Reduction of 8=3. (2.8 g, 8.1 mmol) with lithium aluminum hydride (0.338 g, 8.9 mmol) in ether (30 ml) as in Example 6 gave 8^4 as a colorless oil.
1H NMR (CDC13): δ 1.01-1.31 (11H, m), 1.45-1.86 (1 IH, m), 3.91 (IH, t), 4.6 (2H, d), 6.9 (2 H, d), 7.23 (2 H, d).
Step C: Preparation of 4-(dicyclohexylmethoxy)benzyl bromide
(8-5)
Figure imgf000043_0001
8-4 (1.93 g, 6.4 mmol) was converted to the bromide using phosphorus tribromide (1.69 g, 2.6 mmol) in ether (25 ml) as in Example 7. Recovered ^5 liquid.
*H NMR (CDC13) δ 1.0-1.32 (1 IH, m), 1.53-1.84 (1 IH, m), 3.91 (IH, t), 4.49 (2H, s), 6.85 (2H, d), 7.25 (2H, d).
Step D: Preparation of 4-amino- 1 -[4-(dicyclohexylmethoxy)- benzyllpyridinium bromide (8-7)
Figure imgf000044_0001
Figure imgf000044_0002
8-5 (183 mg, 0.5 mmol) and 4-aminopyridine 8^6 (47 mg, 0.5 mmol) were reacted in acetonitrile (4 ml) as in Example 1 : Recovered white solid 8-7. mp: 248-249°C iH NMR (d6-DMSO) δ 0.94-1.28 (1 IH, m), 1.5-1.75 (1 IH, m), 4.1 (IH, t), 5.24 (2H, s), 6.83 (2H, d), 6.98 (H, d), 7.28 (2H, d), 8.14 (2H, s), 8.3 (2H, d).
Analysis calculated for C25H35N2θBr
C, 65.35; H, 7.68; N, 6.10 Found: C, 65.45; H, 7.62; N, 6.17 EXAMPLE 9
Preparation of 3,4-diamino-l-(4-benzyloxybenzyl)pyridinium bromide (9-7)
Step A: Preparation of 4-benzyloxybenzyl bromide (9-2)
Figure imgf000045_0001
9-2
To a cold suspension of 4-benzyloxybenzyl alcohol 9Λ, (21.4 g, 0.10 mol) in ether (250 ml) was added phosphorus tribromide (10.8 g, 40 mmol) as in Example 7. Recovered 27.2 g of white solid which was recry stallized from hexane (200 ml). Obtained pure bromide 9-2. iH NMR (CDCI3) δ 4.5 (2H, s), 5.05 (2H, s), 6.94 (2H, d), 7.26-7.45 (7H, m). Step B: Preparation of 3,4-diamino-l-(4-benzyloxybenzyl)- pyridinium bromide (9-4)
Figure imgf000046_0001
9-2 (1.38 g, 5.0 mmol) was reacted with 3,4- diaminopyridine (9-3) (0.573 g, 5.25 mmol) in acetonitrile (50 ml) as in Example 1. Recovered white solid 9-4. Recrystallized from acetonitrile, mp: 240-241 °C. iH NMR (d6-DMSO) δ 5.1 (2H, s), 5.25 (2H, s), 5.56 (2H, s),'6.74 (IH, d), 7.05 (2H, d), 7.24-7.46 (9H, m), 7.61 (IH, s), 7.96 (IH, d). Analysis calculated for (Cl9H2oN3θ+Br): (0.25 Et2θ)
C, 59.09; H, 5.22; N, 10.88 Found: C, 59.33; H, 5.60; N, 10.38
The compounds shown in the table below are exemplary compounds of the present invention. The range of Ki values associated with the specifically listed compounds is represented as follows:
+ <0.1 μM
++ >0.1 μM and <1.0 μM
+++ >1.0 μM TABLE I
Figure imgf000047_0001
Figure imgf000047_0004
Figure imgf000047_0002
Figure imgf000047_0003
R Ri Z Y R2 Ki mp
(thr)
Figure imgf000048_0001
Figure imgf000048_0004
Figure imgf000048_0002
Figure imgf000048_0003
The general procedure outlined in Scheme II can be used to make the following compounds.
EXAMPLE 10
Preparation of N-4-(4-benzyloxybenzyl)aminopyridine (10-3)
Step A:
Figure imgf000049_0001
Method 1 : Preparation of 4-(4-benzyloxyphenyl)carboxamido- pyridine (10-2)
A solution of
Figure imgf000049_0002
10-1
(1.1 g, 4.8 mmol), 1 -hydroxybenzotriazole (HOBT) (1.0 g, 7.4 mmol), " l-ethyl-3-(3-dimethylaminopropyl) carbodiimide«HCl (EDC) (1.4 g, 7.3 mmol), Et3N (1 ml, 7.6 mmol) in DMF (40 ml) was treated under N2 with 4-aminopyridine (4-AP) (0.54 g, 5.0 mmol). After stirring overnight at room temperature, the reaction was poured into saturated NaHC03 and extracted with EtOAc (3x). The organic layers were washed with H2θ and brine, dried, filtered and concentrated to dryness. The residue was triturated with hexane to yield 10-2. mp: 126-7°C; ΪH NMR (CDCI3) δ 5.15 (2H, s), 7.04 (2H, d), 7.4 (5H, m), 7.6 (2H, d), 7.84 (2H, d), 8.12 (IH, exch bs), 8.42 (2H, d). Method 2:
Oxalyl chloride (3.3 g, 26 mmol) was added under N2 dropwise to a suspension of 10-1 (5.0 g, 22 mmol) in CH2CI2 (75 ml) with 4 drops of DMF. After 1 h the solution was concentrated to dryness and flushed once with CHCI3. The residue was dissolved in CHCI3 (60 ml) and added dropwise to a suspension of 4-AP (6.2 g, 66 mmol) in CHCI3 (100 ml). After 1 h at room temperature the solution was poured into saturated Na2Cθ3 and separated. The aqueous was further extracted with EtOAc (3x). The combined extracts were dried, filtered and concentrated to dryness. The residue was chromatographed on a Still column (80 mm) and the product eluted with 10% CH3OH- CHCI3 to yield 10-2.
Figure imgf000050_0001
10-3
Preparation of 10-3:
A solution of 10^2 (3.5 g, 1 1.5 mmol) in THF (40 ml) was treated dropwise under N2 with 1.0 M LAH in THF (17 ml, 17 mmol). After addition, the solution was heated at 60°C. After 18 h, the solution was treated with saturated Na2S04 to a white suspension. The mixture was filtered and the pad washed with EtOAc (200 ml). The organic extracts were washed with saturated Na2C03, dried, filtered and concentrated to dryness to yield 10-3. An analytical sample was crystallized as the HCI salt from EtOH-Et2θ; mp: 224-6°C; iH NMR (d6-DMSO) δ 4.45 (2H, s), 5.1 (2H, s), 6.95 (4H, d and m),
7.4 (7H, m), 8.2 (2H, d), 9.2 (IH, exch bs).
Analysis calculated for C 19H 18N2O-HC1-0.25 H2O
C, 68.87; H, 5.93; N, 8.46 Found: C, 68.49; H, 5.80; N, 8.25 EXAMPLE 1 1
Preparation of N-4-(l .l-diphenylmethoxy)benzylaminopyridine (11 -1)
The desired compound was prepared as described in Example 10 using Method 1 in Step A and then Step B; mp: 220-1° (EtOH-Et20); iH NMR (d6-DMSO) δ 3.4 (IH, exch bs), 4.4 (2H, s), 6.5 (IH, s), 6.9 (2H, dd), 7.05 (2H, d), 7.6 (8H, m), 7.5 (4H, d), 8.15 (2H, dd), 9.1 (IH, exch t).
Analysis calculated for C25H22N20ΗC1-3/4 H2O
C, 72.10; H, 5.93; N, 6.75 Found: C, 72.35; H, 5.71; N, 6.97
EXAMPLE 12
Preparation of N-4-(cvclohexylmethoxy)benzylaminopyridine (12-1 )
The desired compound was prepared as described for 10-3 in Example 10 using Method 1 in Step A and then Step B; mp: 273-4°C (EtOH); ΪH NMR (d6-DMSO) δ 1.1 (5H, m), 1.7 (6H, m), 3.75 (2H, s), 4.45
(2H, s), 6.9 (4H, bd), 7.28 (2H, bd), 8.15 (2H, bd), 9.25 (IH, exch bs). Analysis calculated for C 19H24N2OΗCI
C 68.55, H 7.57, N 8.42 Found: C 68.35, H 7.53, N 8.33
EX AMPLE 13
Preparation of 4-[4-(2-methyl-l-phenylpropoxy)benzylamino]pyridine
(13-2)
Step A: Preparation of l -phenyl-2-methyl-l-propanol (13-2)
Figure imgf000052_0001
Isobutyrophenone 13-1 (29.6 g, 0.20 mmol) was dissolved in ethanol (300 ml) and was reduced under N2 with sodium borohydride (7.57 g, 0.20 mmol) for 4 hrs. at room temperature. The ethanol was removed in vacuo and the residue was taken up in ethyl acetate (200 ml) and water (100 ml). The ethyl acetate extract was washed with water, dried, filtered and concentrated in vacuo to obtain alcohol 13-2. iH NMR (CDC13): δ 0.82 (3H, d), 1.0 (3H, d), 1.83 (IH, s), 2.0 (IH, m), 4.4 (IH, d), 7.26 (5H, m).
Step B: Preparation of ethyl 4-(2-methyl-l-phenyl- propoxy)benzoate (13-5)
Figure imgf000053_0001
COC2H£
Figure imgf000053_0002
1 3.4 COOC2H5
Sodium hydride (60% in mineral oil) (200 mg, 5 mmol) was washed with hexane under nitrogen and was suspended in anhydrous ether (30 ml). To the stirred suspension was added 13-2 (7.5 g, 50 mmol) in ether (10 ml) and the mixture was stirred at RT for 1/2 hr. After cooling to -5°C, trichloroacetonitrile (7.58 g, 52.5 mmol) was added. Stirring was continued for 1/2 hr. at 0°C and at ambient temperature for 1 hr. The ether was removed in vacuo and the residual oil 13-3 was taken up in cyclohexane (20 ml) and methylene chloride (10 ml). To this solution was added ethyl 4-hydroxybenzoate (13-4) (8.3 g, 50 mmol) followed by methylene chloride (25 ml) and trifluoromethanesulfonic acid (0.2 ml). The mixture was stirred at ambient temperature overnight and was filtered and concentrated to an oil. Chromatography on silica gel gave 13-5. iH NMR (CDC13) δ 0.91 (3H, d), 1.05 (3H, d), 1.32 (3H, t), 2.15 (IH, m), 4.3 (2H, q), 4.88 (IH, d), 6.83 (2H, d), 7.2-7.4 (5 H, m), 8.7 (2H, d). Step C: Preparation of 4-(2-methyl-l-phenylpropoxy)benzoic acid (13-6)
Figure imgf000054_0001
Figure imgf000054_0002
13-6
To 1M (8.89 g, 29.8 mmol) was added 2N potassium hydroxide (100 ml) and ethanol (50 ml). The mixture was stirred at 100°C overnight. The ethanol was removed in vacuo and the aqueous solution was cooled in ice and acidified with 6N HCI (35 ml, 0.21 mol). The acid was extracted into ethyl acetate (50 ml) and the extract was washed with water, dried, filtered and concentrated in vacuo to obtain the oil 13-6. which solidified. The white solid melted at 125-129°C. iH NMR (CDC13) δ 0.91 (3H, d), 1.05 (3H, d), 2.15 (IH, m), 4.9 (IH, d), 6.85 (2H, d), 7.2-7.35 (5H, m), 7.91 (2H, d).
Step D: Preparation of 4-(2-methyl-l-phenylpropoxy)benzoyl chloride (13-7)
Figure imgf000055_0001
13-6 (0.541 g, 2.0 mmol) was stirred in methylene chloride (3 ml) at room temperature and oxalyl chloride (0.381 g, 3.0 mmol) was added. After 3 hrs. at room temperature the solution was concentrated in vacuo to a pale yellow liquid 13-7. The acid chloride was used without purification.
StepJE: Preparation of 4-(2-methyI-l-phenylρropoxy)-N-(4- pyridyDbenzamide (13-9)
Figure imgf000056_0001
To an ice cold stirred solution of 13-8 (0.188 g, 2.0 mmol) and triethylamine (0.233 g, 2.0 mmol) in tetrahydrofuran (10 ml) was added a solution 13-7 (0.54 g, 2.0 mmol) over a 5-10 min period. The reaction was stirred at ambient temperature overnight. Then the THF was removed in vacuo and the residue was taken up in ethyl acetate (50 ml) and water (25 ml). The ethyl acetate extract was separated, washed with water, dried and concentrated in vacuo to yield the oil 13-9. iH NMR (d6-DMSO) δ 0.84 (3H, d), 1.02 (3H, d), 2.12 (IH, m), 5.2 (IH, d), 7.0 (2H, d), 7.2-7.4 (5H, m), 7.72 (2H, d), 7.82 (2H, d), 8.42 (2H, d), 10.33 (IH, s).
Step F: Preparation of 4-[4-(2-methyl-l -phenylpropoxy)- benzylaminolpyridine (13-10)
LiAIH4 N2
Figure imgf000057_0001
Figure imgf000057_0002
To a stirred suspension of lithium aluminum hydride (0.152 g, 4.0 mmol) in ether (5 ml) under nitrogen was added a solution of 13-9 (0.71 g, 2.0 mmol) in tetrahydrofuran (5 ml) over a 5 min period. The mixture was stirred at ambient temperature overnight and then was decomposed by adding water and sodium hydroxide. Ethyl acetate (25 ml) was added and the mixture was filtered. The filtrate was dried, filtered and concentrated in vacuo to 620 mg of colorless oil which was chromatographed on silica gel. 13-10 was obtained as an oil. The hydrochloride salt melted at 186-188°C. iH NMR (d6-DMSO) δ 0.5 (3H, d), 0.99 (3H, d), 1.16 (IH, t), 4.15 (2H, d), 4.99 (IH, d), 6.47 (2H, d), 6.82 (2H, d), 7.05 (IH, t), 7.12 (2
H, d), 7.2-7.25 (IH, m), 7.25-7.36 (4H, m), 7.96 (2H, d). Analysis calculated for (C22H24N2θ«HCl« 0.2 H2θ)
C, 70.93; H, 6.87; N, 7.52 Found: C, 70.99; H, 6.79; N, 7.62 EX AMPLE 14
Preparation of 4-r4-(2.2-diphenylethoxy)benzylaminolpyridine (14-7)
Step A: Preparation of ethyl 4-(2.2-diphenylethoxy)benzoate (14-3)
Figure imgf000058_0001
To 2,2-diphenylethanol (14-1) (5.95 g, 30 mmol) was added ethyl 4-hydroxybenzoate (14-2) (5.40 g, 30 mmol), triphenylphosphine (8.66 g, 33 mmol) and tetrahydrofuran (125 ml). The mixture was cooled in ice and diethyl azodicarboxylate (5.75 g, 33 mmol) was added. The reaction mixture was stirred under nitrogen at ambient temperature overnight and then the volatile components were removed in vacuo. The oil-solid residue was taken up in ethyl acetate (100 ml) and water (50 ml). Work up of the ethyl acetate portion give crude solid. The product 14-3 was purified by silica gel chromatography. iH NMR (CDC13) δ 1.37 (3H, t), 4.33 (2H, q), 4.52 (3H, s), 6.9 (2H, d), 7.4-7.66 (10H, m), 7.96 (2H, d). Step B: Preparation of 4-(2.2-diphenylethoxy)benzoic acid (14-4)
Figure imgf000059_0001
A suspension of 14-3 (346 mg, 1.0 mmol) in 10% aqueous sodium hydroxide (15 ml) and ethanol (5 ml) was stirred at 100°C ovemight. The resulting solution was cooled and acidified witii excess HCI. A gum separated which was extracted into ethyl acetate (15 ml), washed with water, dried, filtered and concentrated in vacuo. The acid 14-4 was a pale yellow solid, mp: 140-146°C. iH NMR (CDC13) δ 4.55 (3H, s), 6.94 (2H, d), 7.21-7.37 (10H, m), 8.04 (2H, d).
Step C: Preparation of 4-(2,2-diphenylethoxy)-N-(4-pyridyl)benz- amide (14-6)
Figure imgf000060_0001
To 14-4 (125 mg, 0.393 mmol), 4-aminopyridine (14-5) (56 mg, 0.59 mmol), 1 -hydroxybenzotriazole hydrate (80 mg, 0.59 mmol) and triethylamine (60 mg, 0.59 mmol) in DMF (5 ml) under nitrogen was added l -ethyl-3-(3-dimethylamino-propyl)carbodiimide hydrochloride (113 mg, 0.59 mmol). The mixture was stirred at ambient temperature ovemight and the DMF was removed under high vacuum. The residual oil was taken up in ethyl acetate (15 ml) and washed with water and saturated sodium chloride, dried, filtered and concentrated to an amber gum 14-6. Step D: Preparation of 4-[4-(2,2-diphenylethoxy)benzyl- aminolpyridine (14-7)
Figure imgf000061_0001
To a solution of 14-6 (0.144 g, 0.365 mmol) in tetrahydrofuran (1 ml) and ether (3 ml) under nitrogen was added lithium aluminum hydride (30 mg, 0.79 mmol). The mixture was stirred at room temperature ovemight and then was decomposed with water and sodium hydroxide. The mixture was filtered and concentrated in vacuo to a colorless oil 14-7 which was purified by silica gel chromatography and converted to the HCI salt, mp: 213- 214.5°C. iH NMR (d6-DMSO) δ 3.36 (IH, s), 4.36-4.58 (6H, d, m), 6.84-7.0
(3H, d, bm), 7.16-7.4 (11H, m), 8.06-8.25 (2H, d), 9.08-9.24 (IH, bs). Analysis calculated for (C22H24N2θ»HCl)
C, 74.48; H, 6.10; N, 6.74 Found: C, 74.89; H, 6.04; N, 6.72 EX AMPLE 15
Preparation of 4-r4-(2-cyclohexylethoxy)benzylamino1pyridine (15-8)
Step A: Preparation of ethyl 4-(2-cvclohexylethoxy)benzoate (15-3)
Figure imgf000062_0001
15-3
2-Cyclohexylethanol 15-1 (3.2 g, 25 mmol) and ethyl 4- hydroxybenzoate 15-2 (4.15 g, 25 mmol) were reacted as in Example 14. The product 15-3 was obtained as a waxy solid. iH NMR (CDC13) δ 1.04 (2H, m), 1.08-1.3 (3H, m), 1.39 (3H, t), 1.42- 1.58 (IH, m), 1.62-1.81 (7H, m), 4.04 (2H, t), 4.35 (2H, q), 6.9 (2H, d), 7.98 (2H, d).
Step B: Preparation of 4-(2-cvclohexylethoxy)benzoic acid (15-4)
Figure imgf000063_0001
Figure imgf000063_0002
Hydrolysis of 15-3 (1.13 g, 3.1 mmol) as in Example 14 gave the acid 15-4 as a white solid, mp, 129-132°C. iH NMR (CDC13) δ 0.9-1.07 (2H, m), 1.08-1.36 (3H, m), 1.43-1.6 (IH, m), 1.6-1.82 (7H, m), 4.06 (2H, t), 6.92 (2H, d), 8.03 (2H, d).
Step C: Preparation of 4-(2-cyclohexylethoxy)benzoyI chloride (15-5)
Figure imgf000063_0003
15-4
Figure imgf000063_0004
The acid chloride was prepared from 15-4 (0.497 g, 2 mmol) as in Example 13. Crude product was obtained as an oil in quantitative yield and was used without further purification. Step D: Preparation of 4-(2-cyclohexylethoxy)-N-(4-pyridyl)- benzamide (15-7)
Figure imgf000064_0001
This amide was prepared from 15-5 (0.53 g, 2 mmol) and 4-aminopyridine (15-6) (0.188 g, 2 mmol) as in Example 13. The solid obtained, 15-7. melted at 123-125°C. iH NMR (d6-DMSO) δ 0.88-1.03 (2H, m), 1.05-1.3 (3H, m), 1.4-1.56 (IH, m), 1.56-1.8 (7H, m), 4.1 (2H, t), 7.08 (2H, d), 7.78 (2H, d), 7.95 (2H, d), 8.45 (2H, d), 10.42 (IH, s).
Step E: Preparation of 4-[4-(2-cyclohexylemoxy)-benzyl- aminolpyridine (15-8)
Figure imgf000065_0001
Reduction of 15-7 (0.52 g, 1.6 mmol) as in Example 13 gave the product 15-8 as a white solid mp 1 15- 120°C. The hydrochloride melted at 227-228°C. iH NMR (d6-DMSO) δ 0.81-1.0 (3H, m), 1.02-1.3 (3H, m), 1.37-1.52
(IH, m), 1.53-1.78 (7H, m), 3.95 (2H, t), 4.43 (2H, d), 6.91 (2H, d),
6.82-7.04 (2H, m), 7.28 (2H, d), 8.15 (2H, d), 9.25 (IH, t); Analysis calculated for C2OH26N2OΗCI
C, 69.24; H, 7.58; N, 8,08 Found: C, 69.16; H, 7.80; N, 8.08
EX AMPLE 16
Preparation of 4-[4-(dicyclohexylmethoxy)-benzyIamino]pyridine (16-8)
Step A: Preparation of ethyl 4-(dicyclohexyimethoxy)benzoate (I6=3J
Figure imgf000066_0001
COOC2H5
Figure imgf000066_0002
Dicyclohexylmethanol (16-1) (6.97 g, 35.5 mmol) and ethyl 4-hydroxybenzoate (16-2) (5.9 g, 35.5 mmol) were reacted as in Example 14 and the product 16-3 was isolated as a colorless oil. iH NMR (CDC13) δ 0.98-1.3 (1 IH, m), 1.35 (3H, t), 1.52-1.86 (11H, m), 4.02 (IH, t), 4.33 (2H, q), 6.91 (2H, d), 7.94 (2H, d). Step B: Preparation of 4-(dicyclohexylmethoxy)benzoic acid (16-4)
Figure imgf000067_0001
Hydrolysis of 16-3 (7.9 g, 23 mmol) as in Example 14 produced slightly crude acid 16-4. iH NMR (CDCI3) δ 0.98-1.32 (1 IH, m), 1.54-1.84 (1 IH, m), 4.05 (IH, t), 6.92 (2H, d), 8.0 (2H, d).
StepjC: Preparation of 4-(dicyclohexylmethoxy)benzyl chloride (16-5)
Figure imgf000068_0001
Figure imgf000068_0002
Preparation of the acid chloride of 16-4 (1.54 g, 5 mmol) as in Example 13 gave the product 16-5 as a pale yellow oil. It was used without purification.
Step D: Preparation of 4-(4-dicyclohexylmethoxy)-N-(4- pyridvDbenzamide (16-7)
Figure imgf000069_0001
4-Aminopyridine 16-6 (0.47 g, 5 mmol) was acylated with 4-(dicyclohexylmethoxy)benzyl chloride 16-5 (5 mmol) as in Example 13 to give the amide 16-7 as a white solid. iH NMR (d6-DMSO) δ 0.97-1.3 (1 IH, m), 1.53-1.76 (11H, m), 4.25 (IH, t), 7.1 (2H, d), 7.76 (2H, d), 7.88 (2H, d), 8.43 (2H, d), 10.38 (IH, s).
Step E: Preparation of 4-[4-(dicyclohexylmethoxy)-benzyl- aminolpyridine (16-8)
Figure imgf000070_0001
Lithium aluminum hydride reduction of 16-7 (1.28 g, 3.3 mmol) as in Example 14 gave product 16-8 as a colorless oil. .The hydrochloride melted at 213-215°C. iH NMR (d6-DMSO) δ 0.93-1.28 (I IH, m), 1.5-1.77 (IIH, m), 4.04
(IH, t), 4.41 (2H, d), 6.95 (4H, d), 7.22 (2H, d), 8.16 (2H, bd), 9.15
(IH, t).
Analysis calculated for C25H34N2θ»HCl
C, 72.35; H, 8.50; N, 6.75 Found: C, 72.63; H, 8.47; N, 6.76 EX AMPLE 17
Preparation of 4-[4-(l,3-diphenyl-2-propoxy)benzylamino]pyridine (17-9)
Step A: Preparation of 1.3-diphenyl-2-propanol (17-2)
Figure imgf000071_0001
17-1 17-2
Reduction of 1 ,3-diphenylacetone 17-1 (21.0 g, 0.10 mole) was accomplished as in Example 13 in quantitative yield. The alcohol 17-2 was a colorless oil. iH NMR (CDC13) δ 1.64 (IH, d), 2.71-2.91 (4H, dd), 4.07 (IH, m), 7.18-7.37 (lOH. m).
Step B: Preparation of ethyl 4-(l ,3-diphenyI-2-propoxy)benzoate
£17=4)
Figure imgf000072_0001
COOC2H5
Figure imgf000072_0002
Reaction of 17-2 (5.3 g, 0.025 mol) and ethyl 4- hydroxybenzoate 17-2 (6.56 g, 0.025 mol) as in Example 14 gave the product 17-4 as a colorless oil.
Step C: Preparation of 4-(l,3-diphenyl-2-propoxy)benzoic acid
02=5)
Figure imgf000073_0001
Hydrolysis of 17-4 (7.47 g, 21 mmol) as in Example 14 gave the acid 17-5 as a viscious oil (4.28 g). iH NMR (CDC13) δ 2.91-3.08 (4H, m), 4.77 (IH, m), 6.84 (2H, d), 7.16-7.33 (10H, m), 7.96 (2H, d).
Step D: Preparation of 4-(l,3-diphenyl-2-propoxy)benzoyl chloride (17-6)
Figure imgf000074_0001
oxalyl chloride
Figure imgf000074_0002
Figure imgf000074_0003
17-6
17-5 (1.66 g, 5 mmol) was converted to the acid chloride 17-6 as in Example 13. The viscous oil was used without further purification.
Step E: Preparation of 4-(l ,3-diphenyl-2-propoxy)-N-(4- pyridyPbenzamide (17-8)
Figure imgf000075_0001
4-Aminopyridine 17-7 (0.471 g, 5 mmol) was acylated with 7-6 (1.75 g, 5 mmol) using the conditions of Example 13. The amide 7-8 was obtained as a solid foam.
Step F: Preparation of 4-[4-(l,3-diphenyI-2-propoxy)-benzyl- aminolpyridine (17-9)
Figure imgf000076_0001
Lithium aluminum hydride reduction of 17-8 (1.36 g, 3.3 mmol) as described in Example 14 gave a quant, yield of the product 17-9 as a viscous oil. The hydrochloride melted at 151-154°C. iH NMR (d6-DMSO) δ 2.88 (4H, d), 4.41 (2H, d), 4.73 (IH, m), 6.9 (2H, d), 6.83-7.0 (2H, m), 7.16-7.82 (12H, m), 8.15 (2H, bd), 9.15 (IH, t).
Analysis calculated for C27H26N2θ»HCl« 0.4 H2O
C, 74.00; H, 6.40; N, 6.39 Found: C, 73.94; H, 6.28; N, 6.30
EXAMPLE 18
Preparation of 4-[4-(3,4-methylenedioxybenzyloxy)benzyl- aminolpyridine (18-7)
Step A: Preparation of ethyl 4-(3,4-methylenedioxybenzyl- oxy)benzoate (1 -3)
Figure imgf000077_0001
COOC2H5
Figure imgf000077_0002
3,4-Methylenedioxybenzyl alcohol 18-1 (6.2 g, 40.0 mmol) and ethyl 4-hydroxybenzoate 1 -2 (6.65 g, 40.0 mmol) were reacted as in Example 14. The desired ester 18-3 was obtained as a white solid.
Step B: Preparation of ethyl 4-(3,4-methylenedioxybenzyl- oxy)benzoic acid (18-4)
Figure imgf000078_0001
18-4
18-3 (2.5 g, 8.3 mmol) was hydrolyzed with lithium hydroxide (0.8 g, 33.4 mmol) in dimethoxyethane (60 ml) and water (30 ml) at room temperature ovemight. Then water (50 ml) was added and the solution was acidified with 6N HCI. Filtered the white solid which had precipitated and obtained a quantitative yield of crude acid which was recrystallized from butyl chloride-ethyl acetate. The pure products 1M melted at 192-194°C. iH NMR (d6-DMSO) δ 5.06 (2H, s), 6.02 (2H, s), 6.9-6.99 (2H, m), 7.02-7.12 (3H, m), 7.9 (2H, d).
Step C: Preparation of 4-(3,4-methylenedioxybenzyloxy)-N-(4- pyridyDbenzamide (18-6)
Figure imgf000079_0001
To 18-4 (0.545 g, 2 mmol) was added 4-aminopyridine 18-5 (0.235 g, 2.5 mmol), 1-hydroxy-benzotriazole hydrate (0.338 g, 2.5 mmol), l-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide (0.479 g, 2.5 mmol) and dry DMF (5 ml) followed by triethylamine (0.35 ml, 2.5 mmol). The mixture was stirred at ambient temperature ovemight. Then the DMF was removed under high vacuum. The residual oil was chromatographed on silica gel to obtain a white solid 18-6.
Step D: Preparation of 4-[4-(3,4-methylenedioxybenzyl- oxy)benzylamino1pyridine (18-7)
Figure imgf000080_0001
18-6 (0.32 g, 0.9 mmol) was reduced with limium aluminum hydride (0.30 g, 8 mmol) as in Example 10. The product 18-7 was obtained as an oil. The hydrochloride salt melted at 190- 193°C. iH NMR (d6-DMSO) δ 4.45 (2H, d), 4.99 (2H, s), 6.02 (2H, s), 6.83-
7.06 (7H, m), 7.3 (2H, d), 8.16 (2H, bd), 9.2 (IH, t). Analysis calculated for C20H 18N2θ3»HCl» 0.2 H2O
C 64.15, H 5.22, N 7.48 Found: C 63.82, H 5.16, N 7.51. The compounds shown in the table below are exemplary compounds of the present invention. The range of Ki values associated with the specifically listed compounds is represented as follows:
+ <0.1 μM
++ >0.1 μM and <1.0 μM
+++ >1.0 μM
Figure imgf000082_0001
TABLE 2
R Rl Ki (thr) mp (HCI) μM
Figure imgf000082_0002
Figure imgf000082_0003
Figure imgf000082_0004
Figure imgf000082_0005
H O +++ 227-8° -CHp— TABLE 2 (CONT'D)
R Rl X Ki (thr) mp (HCI) μM
Figure imgf000083_0001
Figure imgf000083_0002
Figure imgf000083_0003
Figure imgf000083_0004
Figure imgf000083_0005
Figure imgf000083_0006
Figure imgf000083_0007
R Rl Ki (thr) mp (HCI) μM
Figure imgf000084_0001
Figure imgf000084_0002
H O +++ 101-2°
"CH2 CH2CH2 (freebase)
Figure imgf000084_0003
Figure imgf000084_0004
EX AMPLE 19
Preparation of 4'-(4-cyclohexylmethyloxy-2-benzylphenylmethyl)- aminopyridine (19-3)
Figure imgf000085_0001
Step A: Preparation of 4-cyclohexylmethyloxy-2-benzyl-benzoic acid (19-2)
Figure imgf000085_0002
A solution of 4-cyclohexylmethyloxybenzoic acid (19-1) (1.00 g, 4.27 mmol, 1 equiv) in tetrahydrofuran (10 mL) was added to a solution of sec-butyllithium (1.3 M, 8.21 mL, 10.7 mmol, 2. 50 equiv) and N, N, N', N'-tetramethylethylenediamine (1.61 mL, 10.7 mmol, 2.50 equiv) in tetrahydrofuran (10 mL) at -100 °C (ethanoI-N2(l)). The resultant orange suspension was stirred at -100 °C for 1 h, then warmed to -78 °C and held at that temperature for 15 min. Benzyl bromide (2.00 mL, 16.8 mmol, 3.93 equiv) was added to the cold reaction mixture, causing the color to change to light yellow. The suspension was stirred at -78 °C for 35 min, then was poured into water (150 mL). The aqueous mixture was acidified to approximately pH 2 with an aqueous 1 N hydrochloric acid solution and was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over magnesium sulfate and were concentrated. The residue was purified by flash column chromatography (40% hexanes in ethyl acetate initially, grading to 100% ethyl acetate) to afford the desired carboxylic acid 19-2 as a white solid.
The coupling 19-2 and 4-aminopyridine and subsequent reduction of the amide product were carried out as described in Example 14 to afford the final product 19-3. iH NMR (400 MHz, CDCI3), δ: 8.12 (br d, 2H, 7=6.4 Hz, PyH), 7.26 (m, 2H, PhH), 7.20 (m, IH, PhH), 7.20 (d, IH 7=8.4 Hz, ArH), 7.09 (br d, IH, 7=7.1 Hz, PhH), 6.80 (d, IH, 7=2.8 Hz, ArH), 6.75 (dd, IH, 7=8.4, 2.6 Hz, ArH), 6.26 (br d, 2H, 7=6.4 Hz, PyH), 4.12 (m, 3H, CH2NH and NH), 4.00 (s, 2H, ArCH2Ph), 3.73 (d, 2H, 7=6.4 Hz, OCH2Cy), 1.86 (br d, 2H, 7= 12.8 Hz, CyH), 1.81-1.65 (m, 4H, CyH), 1.37-1.13 (m, 3H, CyH), 1.05 (qd, 2H, 7= 12.1 , 2.9 Hz, CyH); mp: 114- 116°C
EXAMPLE 20
Preparation of 4-(4-cycIohexylmethyloxy-2-benzyloxybenzyl)amino- pyridine (20-6)
Figure imgf000086_0001
Step A: Preparation of Methyl-(4-cyclohexylmethyloxy-2- hydroxy)benzoate (20-2)
Figure imgf000087_0001
20-2
Cyclohexylmethyl bromide (4.56 mL, 32.67 mmol, 1.1 equiv) was added to a suspension of methyl 2,4-dihydroxy-benzoate (20- 1) (5.0 g, 29.7 mmol, 1 equiv) and cesium carbonate (33.9 g, 104.1 mmol, 3.5 equiv) in N, N-dimethylformamide (100 mL) at 23°C. The reaction mixture was heated to 70°C and was stirred at that temperature for 5 h. The solution was cooled to 23°C and was concentrated. The residue was diluted with ethyl acetate, and the resulting solution was washed with an aqueous saturated ammonium chloride solution (2 x 25 mL). The combined aqueous layers were further extracted with 50% ethyl acetate in hexane (2 x 100 L). The combined organic layers were dried over magnesium sulfate and were concentrated. The residue was purified by flash column chromatography (3% ethyl acetate in hexanes) to afford
Figure imgf000087_0002
(UV)TLC (5% EtOAc- hexane), Rf.= 0.51 (UV); iH NMR (400 MHz, CDCI3), δ: 10.94 (s, IH, OH), 7.71 (d, IH, 7 = 9.52 Hz, ArH [ortho to CO2CH3]), 6.41 (m, 2H, ArH [ eta to CO2CH3]), 3.90 (s, 3H, CO2CH3), 3.76 (d, 2H, 7=6.04 Hz, OCH2Cy), 1.77 (m, 6H, CyH), 1.26 (m, 3H, CyH), 1.05 (m, 2H, CyH). StepJB: Preparation of Methyl(4-cyclohexylmethyloxy-2- benzyloxy)benzoate (20-3)
Figure imgf000088_0001
20-2 20-3
Benzyl bromide (0.216 mL, 1.81 mmol, 1.2 equiv) was added to a suspension of 20-2 (400 mg, 1.51 mmol, 1 equiv) and cesium carbonate (1.72 g, 5.30 mmol, 3.5 equiv) in N, N-dimethylformamide (15 mL) at 23°C. The reaction mixture was heated to 70°C and was stirred at that temperature for 2h. The solution was cooled to 23°C and was concentrated. The residue was diluted with ethyl acetate (60 mL), and the resulting solution was washed with an aqueous saturated ammonium chloride solution (2 x 30 mL). The organic layer was dried over magnesium sulfate and was concentrated to afford the product 20-3 as a pale yellow oil which was used without further purification. *H NMR (400 MHz, CDCI3), δ: 7.87 (d, IH, 7 = = 8.61 Hz, ArH [ortho to CO2CH3]), 7.53 (d, 2H, 7=7.32 Hz, PhH), 7.39 (d, 2H, 7= 6.95 Hz, PhH), 7.32 (m, IH, PhH), 6.53 (s, IH, ArH [meta to CO2CH3]), 6.51 (d, IH, 7=8.79 Hz, ArH [meta to CO2CH3]), 5.17 (s, 2H, CH2Ph), 3.87 (s, 3H, CO2CH3), 3.77 (d, 2H, 7=6.22 Hz, CH2Cy), 1.85 (d, 2H, 7= 13.36 Hz, CyH), 1.76 (m, 4H, CyH), 1.27 (m, 2H, CyH), 1.05 (m, 2H, CyH); TLC (10% EtOAc-hexane), Rf: = 0.14 (UV) Step C: Preparation of (4-cyclohexylmethyloxy-2-benzyl- oxy)benzoic acid (20-4)
Figure imgf000089_0001
20-3 20-4
A solution of sodium hydroxide (302 mg, 7.55 mmol, 5 equiv) in water (3 mL) was added to a solution of 20-3 (1.51 mmol, 1 equiv) in 1 ,4-dioxane (7 mL). The reaction mixture was heated at reflux for 16 h. The solution was cooled to 23°C, and then was diluted with ethyl acetate (60 mL). The organic layer was washed with an aqueous 10% potassium hydrogen sulfate solution (2 x 30 mL) and was dried over magnesium sulfate and was concentrated to afford 20-4 as a white solid, which was used without further purification. iH NMR (400 MHz, CD3OD), δ: 7.85 (d, IH, 7 = = 8.79 Hz, ArH [ortho to C02H]), 7.51 (d, 2H, 7 = = 7.51 Hz, PhH), 7.35 (m, 3H, PhH), 6.65 (d, IH, 7 = = 2.01 Hz, ArH [meta to CO2H]), 6.57 (dd, IH, 7 = = 8.79, 2.20 Hz, ArH [meta to CO2H], 5.25 (s, 2H, CH2Ph), 3.80 (d, 2H, 7 = = 6.22 Hz, CH2Cy), 1.85 (d, 2H, 7 = = 14.10 Hz, CyH), 1.76 (m, 4H, CyH), 1.29 (m, 3H, CyH), 1.10 (m, 2H, CyH). StepJD: Preparation of N-4-pyridyl-(4-cyclohexylmethyloxy-2- benzyloxy)benzamide (20-5)
Figure imgf000090_0001
20-4
Oxalyl chloride (0.391 mL, 4.49 mmol, 3 equiv) was added to a solution of 20-4 (509 mg, 1.49 mmol, 1 equiv) in dichloromethane (6 mL) at 23°C. Once gas evolution ceased (approximately 5 min after the addition of oxalyl chloride), the volatiles were removed in vacuo. The residue was dissolved in dichloromethane (11 mL), and the resulting solution was transferred via cannula to a suspension of 4- aminopyridine (704 mg, 7.47 mmol, 5 equiv) and triethylamine (1.67 mL, 11.96 mmol, 8 equiv) in dichloromethane (10 mL) at 23°C. The reaction mixture was stirred for 2 h at 23 °C, then was concentrated in vacuo. The residue was purified by flash column chromatography (15% hexanes in ethyl acetate) to afford the product 20-5 as a white solid.
!H NMR (400 MHz, CDC13), δ: 9.99 (s, IH, NH), 8.34 (d, 2H, 7 = = 4.95 Hz, PyH), 8.24 (d, IH, 7 = = 8.79 Hz, ArH [meta to OCH2Cy]), 7.55 (d, 2H, 7 = = 7.69 Hz, PhH), 7.52 (m, 3H, PhH), 7.06 (dd, 2H, 7 = = 4.95, 1.28 Hz, PyH), 6.68 (d, IH, 7 = = 8.79 Hz, ArH [ortho to OCH2Cy]), 6.65 (s, IH, ArH [ortho to OCH2Cy]), 5.19 (s, 2H, CH2Ph), 3.85 (d, 2H, 7 = = 6.23 Hz, CH2Cy), 1.89 (d, 2H, 7 = = 12.64 Hz,
CyH), 1.77 (m, 4H, CyH), 1.29 (m, 2H, CyH), 1.09 (m, 2H, CyH); TLC (100% EtOAc), Rf. = 0.38 (UV) Step E: Preparation of 4-(4-cyclohexylmethyloxy-2-benzyl- oxybenzyDaminopyridine (20-6)
Figure imgf000091_0001
20-5
Figure imgf000091_0002
20-6
A solution of lithium aluminum hydride in tetrahydrofuran (1.0 M, 4.12 mL, 4.12 mmol, 4 equiv) was added to a solution- of 20-5 (430 mg, 1.03 mmol, 1 equiv) in tetrahydrofuran (3 mL) at 0°C. The reaction mixture was heated to 50°C and held at that temperature for 2 h. The mixture was cooled to 0°C, and excess lithium aluminum hydride was quenched by the consecutive addition of water (0.155 mL), aqueous 15% sodium hydroxide solution (0.155 mL), and water (0.467 mL). The resulting aluminum salts were removed by filtration. The filtrate was concentrated, and the residue was purified by flash column chromatography (0.5% methanol in chloroform saturated with ammonia) to afford the product 20-6 as a white solid (mp = 131-132°C, 330 mg, 80%). iH NMR (400 MHz, CDCI3), δ: 8.16 (dd, 2H, 7 = = 4.77, 1.46 Hz, PyH), 7.37 (m, 5H, PhH), 7.15 (d, IH, 7 = = 8.24 Hz, ArH [meta to OCH2Cyj), 6.57 (d, IH, 7 = = 2.02 Hz, ArH [ortho to OCH2Cy]), 6.46 (dd, IH, 7 = = 8.24, 2.19 Hz, ArH [ortho to OCH2Cy]), 6.43 (dd, 2H, 7 = = 4.77, 1.46 Hz, PyH), 5.09 (s, 2H, CH2Ph), 4.50 (br s, IH, NH), 4.32 (d, 2H, 7 = = 5.86 Hz, CH2NH), 3.73 (d, 2H, 7 = = 6.41 Hz, CH2Cy), 1.86 (d, 2H, 7 = = 12.27 Hz, CyH), 1.75 (m, 4H, CyH), 1.27 (m, 3H, CyH), 1.04 (m, 2H, CyH); TLC (0.5% CH3OH- CHCI3 sat'd
Figure imgf000092_0001
EXAMPLE 21
Preparation of 4-{ [3-amino-4-(cyclohexylmethyloxy)phenyl]methyl- aminolpyridine dihvdrochloride (21 -6)
Step A: Preparation of Ethyl 4-(cyclohexylmethyloxy)-3- nitrobenzoate (21-2)
Figure imgf000092_0002
21-1
Figure imgf000092_0003
To a mixture of ethyl 4-hydroxy-3-nitrobenzoate (21-1 ) (2.1 lg, 10.0 mmol), cesium carbonate (6.52 g, 20.0 mmol), and sodium iodide (0.15g, 1.0 mmol) in DMF (20 ml) under nitrogen was added cyclohexylmethylbromide (1.67 ml, 12.0 mmol). The mixture was stirred 48h at 60°C. The resulting mixture was evaporated under reduced pressure. To the residue was added water (100 ml), and the aqueous mixture was extracted with methylene chloride (2 x 200 ml). The organic fraction was washed with saturated sodium carbonate solution (100 ml) and brine (100 ml), dried (sodium sulfate), and the solvent was evaporated under reduced pressure. The residue was crystallized from ether/hexane to give product 21 -2 as yellow crystals, mp: 79-80°C. iH NMR (CDC13) δ 8.49 (IH, d, 7=2 Hz), 8.19 (IH, dd, 7=9, 2 Hz), 7.09 (IH, d, 7=9 Hz), 4.39 (2H, q, 7=7 Hz), 3.95 (2H, d, 7=6 Hz), 1.69- 1.89 (6H, m), 1.40 (3H, t, 7=7 Hz), 1.06-1.38 (5H, m).
Step B: Preparation of 4-(cyclohexylmethyloxy)-3-nitrobenzoic acid (21-3)
To a solution of 2 2 (1 -38 g, 4.50 mmol) in THF (22.5 ml) cooled in an ice-bath was added IN lithium hydroxide solution (22.5 ml). The resulting solution was stirred 18h while warming to ambient temperature. The solution was partially evaporated at reduced pressure, and the remaining aqueous solution was washed with etfiyl acetate (20 ml). The aqueous layer was cooled in an ice-bath, stirred rapidly, and concentrated hydrochloric acid (2 ml) was added dropwise, resulting in formation of a precipitate. The mixture was stirred lh, the precipitate was collected and dried in vacuo to give product 21 -3 as a white solid, mp: 200-202°C. iH NMR (CDCI3) δ 8.56 (IH, d, 7=2 Hz), 8.24 (IH, dd, 7=9, 2 Hz), 7.13 (IH, d, 7=9 Hz), 3.98 (2H, d, 7=6 Hz), 1.70-1.90 (6H, m), 1.08- 1.40 (5H, m).
Step C: Preparation of N-(4-pyridyl)-4-(cyclohexylmethyloxy)- 3-nitrobenzamide (21-4)
Figure imgf000093_0001
To a mixture of 2 3 (0.307 g, 1.1 mmol) and DMF (I drop) in methylene chloride (3 ml) under nitrogen cooled in an ice-bath was added dropwise a solution of oxalyl chloride (0.1 13 ml, 1.3 mmol) in methylene chloride (1 ml). The resulting solution was stirred lh with ice-bath cooling, lh at ambient temperature, then was evaporated at reduced pressure to give crude 4-(cyclohexylmethyloxy)-3- nitrobenzoyl chloride as an oil.
To a mixture of the crude 4-(cyclohexylmethyloxy)-3- nitrobenzoyl chloride in methylene chloride (2 ml) under nitrogen cooled in an ice-bath was added dropwise a solution of 4-aminopyridine (0.282 g, 3.0 mmol) in methylene chloride (1 ml). The resulting solution was stirred lh with ice-bath cooling, then 2h at ambient temperature. The mixture was diluted with methylene chloride (10 ml) and washed with saturated sodium bicarbonate solution (5 ml). The aqueous layer was extracted with methylene chloride (2 x 10 ml). The combined organic fractions were washed with water (10 ml), brine (10 ml), dried (sodium sulfate), and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with methano ethyl acetate (5:95), to give a solid. The solid was recrystallized from ethyl acetate to give the product 21 -4 as white crystals, mp: 197-198°C. iH NMR (CDC13) δ 8.57 (2H, d, 7= 6 Hz), 8.37 (IH, d, 7= 2 Hz), 8.14 (2H, m), 7.62 (2H, d, 7= 8 Hz), 7.13 (IH, d, 7= 9 Hz), 3.98 (2H, d, 7= 6
Hz), 1.71 -1.90 (6H, m), 1.08-1.38 (5H, m). Analysis calculated for C19H21N3O4 C, 64.21; H, 5.96; N, 11.82 Found: C, 64.18; H, 5.97; N, 11.70
StepJD: Preparation of N-(4-pyridyl)-3-amino-4-(cyclohexyI- methyloxy)benzamide (21-5)
Figure imgf000095_0001
A mixture of 21-4 (0.171g, 0.48 mmol) and 10% palladium on carbon (0.040g) in ethanol (50 ml) was shaken on a Parr hydrogenation apparatus under hydrogen (50 psi) for 20h. The mixture was filtered through filter aid and the filtrate was evaporated under reduced pressure to give a solid. The solid was dissolved in hot ethyl acetate (50 ml), treated with charcoal, and the mixture was filtered through filter aid. The filtrate was evaporated to one-third volume and cooled. The resulting precipitate was collected and dried in vacuo to give product 21-5 as a white crystalline solid, mp: 193-194°C. iH NMR (CDC13) δ 8.52 (2H, d, 7=6 Hz), 7.89 (IH, br s), 7.58 (2H, d, 7=6 Hz), 7.25 (IH, d, 7=2 Hz), 7.20 (IH, dd, 7=8, 2 Hz), 6.80 (IH, d, 7= 8 Hz), 3.98 (2H, br s), 3.86 (2H, d, 7=6 Hz), 1.66-1.91 (6H, m), 1.08-
1.38 (5H, m);
Analysis calculated for C 19H23N3θ2#0.10 ethyl acetate
C, 69.71; H, 7.18; N, 12.57 Found: C, 69.71; H, 7.17; N, 12.57
Step E: Preparation of 4-{ [3-amino-4-(cyclohexylmethyl- oxy)phenvπmethylamino)pyridine dihydrochloride (21 -6)
Figure imgf000096_0001
In a dry three-necked round bottom flask equipped with a condenser, nitrogen inlet, and septum, was placed a solution of 21-5 (0.059 g, 0.18 mmol) in anhydrous THF (2 ml). To the solution was added 2.0M borane-dimethylsulfide complex in THF (0.38 ml, 0.76 mmol) dropwise via syringe. The resulting mixture was stirred lh at 60°C. The mixture was cooled to ambient temperature, and 6N hydrochloric acid (1 ml) was added dropwise. The mixture was heated in a 60°C oil-bath for five minutes, cooled to ambient temperature, and poured into saturated sodium carbonate solution (10 ml). The mixture was extracted with ethyl acetate (3 x 20 ml). The combined organic fractions were washed with brine (20 ml), dried (sodium sulfate), and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with methano ethyl acetate (10:90), to give a gummy solid. The solid (0.052g) was suspended in ethanol (1 ml) and ethanolic HCI (6 M, 0.065 ml, 0.39 mmol) was added. The mixture was stirred, diluted with ether (10 ml), and the resulting precipitate was collected and dried in vacuo to give 21-6. as a white solid, mp: 173-175°C. lH NMR (DMSO-d6) δ 9.26 (IH, t, 7=6 Hz), 8.7-9.8 (2H, br s), 8.22 (IH, d, 7=7 Hz), 8.1 1 (IH, d, 7=7 Hz), 7.25 (IH, s), 7.19 (IH, d, 7=8 Hz), 7.09 (IH, d, 7=8 Hz), 7.00 (I H, dd, 7=7, 2 Hz), 6.85 (IH, dd, 7=7, 2 Hz), 4.47 (2H, d, 7=6 Hz), 3.84 (2H, d, 7=6 Hz), 3.3-4.1 (2H, br s), 1.86 (2H, d, 7= 12 Hz), 1.60-1.82 (4H, m), 1.1 1-1.32 (3H, m), 1.00-1.10 (2H, m); Analysis calculated for C 19H25N3θ»2 HCl'0.25 H2θ
C, 58.68; H, 7.13; N, 10.81 Found: C, 58.64; H, 6.99; N, 10.72
Figure imgf000097_0001
Step F: Preparation of 4- [ [3-emylammo-4-(cyclohexylmethyl- oxy)phenyllmethylaminolpyridine dihvdrochloride (21 -7c) Step 1 : To a mixture of V-(4-pyridyl)-3-amino-4-(cyclohexyl- methyloxy)benzamide (21 -7a) (0.065 g, 0.20 mmol) in methylene chloride (1 ml) under nitrogen cooled in ice-bath was added acetic anhydride (0.040 ml, 0.42 mmol). The resulting mixture was stirred with ice-bath cooling for 2 h. The mixture was diluted with methylene chloride (4 ml), washed with 10% citric acid solution (2 ml), water (2 ml), saturated sodium bicarbonate solution (2 ml), water (2 ml), and brine (2 ml), dried over sodium sulfate, and concentrated in vacuo to give -(4-pyridyl)-3-amino-4-(cyclohexylmethyloxy)benzamide (21 -7b) (0.060 g, 82%) as a foam. dH(CDCl3) 8.84 (IH, d, 72 Hz), 8.52 (2H, d, 7 6 Hz), 8.46 (IH, br s), 7.81 (IH, br s), 7.76 (IH, dd, 79,2 Hz), 7.65 (2H, dd, 7 5,1 Hz), 6.96 (IH, d, 7 8 Hz), 3.91 (2H, d, 7 6 Hz), 2.24 (3H, s), 1.70-1.95 (6H, m), 1.07-1.42 (5H, m).
Step 2: Employing the procedure substantially as described for the preparation of 21-6. but starting with 21 -7b (0.055g, 0.15 mmol), 21 -7c was obtained as a white solid, mp: 137-145°C. dH(DMSO-d6) 9.16 (IH, bs), 8.22 (IH, m), 8.13 (IH, m), 6.95-7.15 (3H, m), 6.97 (IH, d, 77 Hz), 6.87 (IH, d, 7 7 Hz), 4.45 (2H, d, 7 5 Hz), 3.83 (2H, d, 7 5 Hz), 3.4-3.8 (2H, br s), 3.18 (2H, q, 77 Hz), 1.60- 1.90
(6H, m), 1.17 (3H, t, 77 Hz), 1.04-1.82 (5H, m). Analysis calculated for C21 H29N30-2 HC1-0.50 H20 C, 59.85; H, 7.65; N, 9.97
Found: C, 59.90; H, 7.49; N, 9.94
Figure imgf000098_0001
Step G: 4- { [3-(phenylmethylsulfonamido)-4-(cyclohexylmethy 1- oxy)phenvnmethylamino)pyridine dihvdrochloride (21 -7e) Step 1: To a mixture of 21 -7a (0.065 g, 0.20 mmol) and pyridine
(0.032 ml, 0.40 mmol) in methylene chloride (2 ml) under nitrogen cooled in ice-bath was added alpha-toluenesulfonyl chloride (0.050 g, 0.26 mmol). The resulting mixture was stirred with ice-bath cooling for 3 h. The mixture was diluted with ethyl acetate (15 ml), washed with saturated sodium bicarbonate solution (5 ml) and brine (5 ml), dried over sodium sulfate, and concentrated in vacuo to give a gum (0.106g). The gum was flash chromatographed on silica gel eluting with ethyl acetate to give V-(4-pyridyl)-3-(phenylmethylsulforiamido)- 4-(cyclohexylmethyl-oxy)benzamide (21 -7d) as a gum. dH(CDCl3) 8.55(1H, d, 76 Hz), 8.06 (IH, bs), 8.46 (IH, br s), 7.80 (IH, d, 7 2 Hz), 7.71 (IH, dd, 79,2 Hz), 7.62 (2H, d, 76 Hz),7.25-7.32 (3H, m), 7.26 (2H, m), 6.94 (IH, d, 7 9 Hz), 6.83 (IH, bs), 4.39 (2H, s), 3.81 (2H, d, 7 6 Hz), 1.65-1.82 (6H, ), 1.13-1.33 (3H, m), 0.90-1.08 (2H, m).
Step 2: Employing the procedure substantially as described for the preparation of 21-6. but starting with 21-7d (0.077 g, 0.16 mmol), 2ά 7e, was obtained as a white solid, mp: 135-140°C. dH(DMSO-d6) 9.07 (IH, bs), 8.79 (IH, bs), 8.17 (2H, d, 7 6 Hz), 7.26- 7.35 (5H, m), 7.19 (IH, d, 7 2 Hz),7.12 (IH, d, 7 8 Hz), 7.03 (IH, d, 7 8 Hz), 6.92 (2H, bs), 4.43 (4H, m), 3.80 (2H, d, 7 6 Hz), 1.62-1.82 (6H, m), 1.12-1.30 (3H, m), 0.95-1.10 (2H, m). Analysis calculated for C26H31 N303S»HC1:
C, 62.20; H, 6.42; N, 8.37 Found: C, 62.31 ; H, 6.44; N, 8.36
EXAMPLE 22
Preparation of 4-{[3-propyl-4-(cyclohexylmethyl- ox v)phenyllmethylamino ) pyridine (22-8)
Figure imgf000100_0001
22-2 COOCHg
22-1
Figure imgf000100_0002
LiAIHd/THF
Figure imgf000100_0003
Step A: Preparation of Methyl 4-allyloxybenzoate (22-2)
Figure imgf000101_0001
To a solution of methyl 4-hydroxybenzoate (22-1) (9.72 g, 64.36 mmol) in 100 mL of DMF was added 24.8 g (76.0 mmol) of CS2CO3 followed by 5.0 mL (58.5 mmol) of allyl bromide. The resulting solution was then heated at 50°C for 5h. The solvent was distilled under reduced pressure and the residue was taken up in 200 mL of EtOAc. The organic phase was extracted with IN NaOH (2 x 50 mL), water (5 x 50 mL) and brine (50 mL), dried (MgS04) and concentrated to afford product 22-2 as a white solid. iH NMR (CDC13) δ 8.00 (d, J=7.8 Hz, 2H), 6.95 (d, J=7.8 Hz, 2H), 6.05 (m, IH), 5.45 (d, IH), 5.30 (d, IH), 4.60 (d, J=6.4 Hz, 2H), 3.85 (s, 3H).
Step B: Preparation of Methyl 4-hvdroxy-3-allylbenzoate (22-3)
Figure imgf000101_0002
22-3
The neat allyl ether 22-2 from Step A (7.0 g, 38.6 mmol) was heated in an oil bath at 230°C for lh. The reaction was followed by NMR and was found to be complete after 90 min. The resulting brown oil was cooled and subjected to column chromatography (1: 1 EtOAc / Hexane) to afford 22-3 as a white solid. iH NMR (CDCI3) δ 7.80 (m, 2H), 6.90 (d, J=7.8 Hz, IH), 6.00 (m, IH), 5.60 (s, IH), 5.20 (s, IH), 5.15 (d, J=6 Hz, IH), 3.85 (s, 3H), 3.45 (d, J=6.4 Hz, 2H), Step C: Preparation of Methyl 4-hvdroxy-3-ρropylbenzoate (22-4)
Figure imgf000102_0001
22-4
To 22-3 (6.0 g, 33.2 mmol) in 50 mL of EtOAc was added 60 mg of 5% Pd on carbon and the whole was hydrogenated at atmospheric pressure for 24h. Hydrogen was removed from the reaction mixture and the solution was filtered through Celite. Evaporation of the solvent afforded product 22-4 as a white solid. ! H NMR (CDC13) δ 7.84 (d, J=1.9 Hz, IH), 7.79 (dd, J=2.0, 8.3 Hz, IH), 6.79 (d, J=8.3 Hz, IH), 5.49 (s, IH), 3.88 (s, 3H), 2.60 (t, J=7.8 Hz, 2H), 1.65 (m, 2H), 0.97 (t, J=7.3 Hz, 3H).
Step D: Preparation of Methyl 4-(cyclohexylmethyloxy)-3- propylbenzoate (22-5)
Figure imgf000102_0002
COOCH,
22-5
To a solution of 22z4 (915 mg, 5.0 mmol) in 10 mL of DMF was added 1.78 g (5.50 mmol) of CS2CO3 followed by 0.68 mL (4.9 mmol) of bromomethyl cyclohexane. The resulting solution was then heated at 50°C for 24h. The solvent was distilled under reduced pressure and the residue was taken up in 20 mL of EtOAc. The organic phase was extracted with IN NaOH (2 x 50 mL), water (5 x mL) and brine (5 mL), dried (MgSθ4) and concentrated to afford 22-5 as an oil. iH NMR (CDC13) δ 7.84 (dd, J=2.4, 8.8 Hz, IH), 7.80 (d, J=2.4, Hz, IH), 6.80 (d, J=8.8 Hz, IH), 3.87 (s, 3H), 3.80 (d, J=15.9 Hz, 2H), 2.60 (t, J=7.8 Hz, 2H), 1.95- 1.00 (m, 13H), 0.93 (t, J=7.3 Hz, 3H). Step E: Preparation of 4-(cyclohexylmethyloxy)-3-propyIbenzoic acid (22-6)
Figure imgf000103_0001
To a solution of 22^5 (1.0 g, 3.44 mmol) in 10 mL of MeOH and 2 mL of THF was added 3.5 mL (14 mmol) of 4N NaOH. The resulting solution was heated at 50°C for 24h, cooled and acidified by the addition of 15 mL of IN HCI. The aqueous phase was extracted with 2 x 40 mL of EtOAc. The organic extracts were washed with brine (5 mL) and dried over MgS04. Evaporation of the solvent afforded 22-6 which was used without purification.
Step F: Preparation of iV-(4-pyridyl)-3-propyl-4-(cyclohexyl- methyloxy)benzamide (22-7)
Figure imgf000103_0002
To a solution of 22-6 (770 mg, 2.78 mmol) in 10 mL of (CH2C1)2 and 0.05 mL of DMF was added 0.26 mL (3.05 mmol) of oxalyl chloride. The resulting solution was heated at 50°C for 30 min, cooled to 0°C and treated with 1.20 g (13.8 mmol) of 4-aminopyridine. Stirring was continued for 2h before the heterogeneous mixture was diluted with 50 mL of EtOAc and quenched with 25 mL of 5% Na2C03. The organic extract was washed with sat'd NH4CI (3 x 50 mL), water (2x 25 mL), brine (25 mL) and dried over MgS04. Evaporation of the solvent and column chromatography (EtOAc) afforded product 22-7.
*H NMR (CDCI3) δ 8.55 (d, J=8.0 Hz, 2H), 8.10 (bs, IH), 7.75 (dd, J=2.4, 8.8 Hz, IH), 7.70 (s, IH), 7.60 (d, J=8.0 Hz, 2H), 6.85 (d, J=8.8 Hz, IH), 3.80 (d, J=15.9 Hz, 2H), 3.70 (s, 3H), 2.60 (t, J=7.8 Hz, 2H), 1.95-1.00 (m, 13H), 0.90 (t, J=7.3 Hz, 3H).
Step G: Preparation of 4-{[3-propyl-4-(cyclohexylmethyl- oxy)phenyllmethylamino ) pyridine (22-8)
Figure imgf000104_0001
To a solution of 22^7 (1.0 g, 2.8 mmol) in 30 mL of THF was added 10.0 mL (10.0 mmol) of LiAlH4 (1M in THF) and the resulting solution was stirred at room temperature for 16 h, cooled to 0°C and quenched with 1 mL of water, 1 mL of 15% NaOH then 3 mL of water. The heterogeneous mixture was diluted with 50 mL of EtOAc and washed with 3 x 5 mL of sodium potassium tartrate, water (2x 5 mL), brine (5 mL) and dried over MgS04. Evaporation of the solvent and column chromatography (9:1 CHCI3 (sat'd NH3)/isopropyl alcohol) afforded 22-8. iH NMR (CDCI3) δ 8.18 (d, J=8.1 Hz, 2H), 7.10 (d, J=7.5 Hz, IH), 7.07 (s, IH), 6.77 (d, J=7.5 Hz, 2H), 6.41 (d, J=8.1 Hz, 2H), 4,45 (bs, IH), 4.24 (d, J=15.9 Hz, 2H), 3.74 (d, J=5.1 Hz, 2H), 2.57 (t, J=7.8 Hz,
2H), 2.00-1.00 (m, 13H), 0.94 (t, J=7.3 Hz, 3H); Analysis calculated for C22H30N2O C, 78.06; H, 8.93, N, 8.28 Found: C, 78.33; H, 8.99; N, 8.56 EXAMPLE 23
Preparation of 4-{ [3-ethyl-4-(cyclohexylmethyloxy)phenyl]methyl- aminolpyridine (23-8)
Figure imgf000105_0001
LiAIH THF
50°C
Figure imgf000105_0002
Step A: Preparation of Methyl 4-cyclohexylmethyIoxy-benzoate
(23-2)
Figure imgf000106_0001
To a solution of methyl 4-hydroxybenzoate 23-1 (24.3 g, 160 mmol) in 250 mL of DMF was added 62 g (190 mmol) of CS2CO3 followed by 20.4 mL (146 mmol) of cyclohexylmethyl bromide. The resulting slurry was then heated at 50°C for 20 h. The solvent was distilled under reduced pressure and the residue was taken up in 500 mL of EtOAc. The organic phase was extracted with IN NaOH (2 x 150 mL), water (5 x 150 mL) and brine (150 mL), dried (MgSθ4) and concentrated to afford product 23-2 as a white solid. iH NMR (CDC13) δ 7.98 (d, J=8.5 Hz, 2H), 6.90 (d, J=8.5 Hz, 2H), 3.88 (s, 3H), 3.78 (d, J=6.1 Hz, 2H), 2.00-1.00 (m, 1 IH).
Step B: Preparation of Methyl 4-cyclohexylmethoxy-3-bromo- benzoate (23-3)
Figure imgf000106_0002
A solution of 23-2 (26.3 g, 106 mmol) was warmed on a steam bath in 1 10 mL of HCOOH with 592 mg (10.6 mmol) of Fe powder. Bromine (7.6 mL, 147.4 mmol) in 50 mL of HCOOH was added by dropping funnel over a period of 10 min. The reaction mixture was stirred an additional lh , cooled and poured onto ice. The resulting gum was taken up in 500 mL of EtOAc and washed with sat'd Na2S2θ3 (2 x 150 mL), water (5 x 100 mL), sat'd NaHCθ3 (3 x 100 mL) and brine (50 mL), dried (MgS04) and concentrated to afford product 23-3 as a white solid.
*H NMR (CDC13) δ 8.22 (s, IH), 7.98 (d, J=8.5 Hz, IH), 6.90 (d, J=8.5 Hz, IH), 3.88 (s, 3H), 3.78 (d, J=6.1 Hz, 2H), 2.00-1.00 (m, 1 1 H). Step C: Preparation of Methyl 4-cyclohexylmethyloxy-3-ethenyl- benzoate (23-4)
Figure imgf000107_0001
To a solution of 23-3 (810 mg, 2.5 mmol) in 1 1.5 mL of dioxane was added 820 mg (2.6 mmol) of vinyltributyl tin followed by 58 mg (0.05 mmol) of Pd(PPh3)4. The resulting solution was then heated at 100°C for 20 h. The solvent was distilled under reduced pressure and the residue was chromatographed to afford product 23-4. iH NMR (CDC13) δ 8.19 (s, IH), 7.85 (d, J=8.5 Hz, IH), 7.00 (dd, J=, IH), 6.92 (m, IH), 5.85 (d, J=Hz, IH), 5.35 (d, J=Hz, IH), 3.88 (s, 3H), 3.78 (d, J=6.1 Hz, 2H), 2.00-1.00 (m, I IH).
Step D: Preparation of Methyl 4-cyclohexylmethyloxy-3-ethyl- benzoate (23-5)
Figure imgf000107_0002
To 23-4 (560 mg, 2.0 mmol) in 15 mL of EtOAc was added 56 mg of 10% Pd on carbon and the whole was hydrogenated at atmospheric pressure for 24h. Hydrogen was removed from the reaction mixture and the solution was filtered through Celite. Evaporation of the solvent afforded 23-5 as a white solid. iH NMR (CDC13) δ 7.84 (dd, J=2.4, 8.8 Hz, IH), 7.80 (d, J=2.4 Hz, IH), 6.80 (d, J=8.8 Hz, IH), 3.87 (s, 3H), 3.80 (d, J=15.6 Hz, 2H), 2.60 (q, J=7.5 Hz, 2H), 1.95-1.00 (m, 14H). Step E: Preparation of 4-cyclohexylmethyloxy-3-ethyl-benzoic acid (23-6)
Figure imgf000108_0001
To a solution of 23-5 (290 mg, 1.0 mmol) in 7.6 mL of THF and 10 mL of water was added 210 mg (5.0 mmol) of LiOH. The resulting solution was stirred for 40h, then acidified by the addition of 10 mL of IN HCI. The aqueous phase was extracted with 2 x 20 mL of EtOAc. The organic extracts were washed with brine (5 mL) and dried over MgS04. Evaporation of the solvent afforded acid 23-6 which was used without purification.
Step F: Preparation of V-(4-pyridyl)-3-ethyl-4-(cyclohexyl- methyloxy)benzamide (23-7)
Figure imgf000108_0002
To a solution of 23-6 (270 mg, 1.0 mmol) in 3.6 mL of CH2CI2 was added 0.13 mL (1.5 mmol) of oxalyl chloride. The resulting solution was stirred for lh, cooled to 0°C and treated with 380 mg (4.0 mmol) of 4-aminopyridine. Stirring was continued for lh before the heterogeneous mixture was diluted with CH2CI2 and quenched with sat'd NaHC03. The organic extract was washed with water, brine and dried over Na2Sθ4- Evaporation of the solvent and column chromatography (3:1 EtOAc / Hexane) afforded product 23-7. iH NMR (CDCI3) δ 8.55 (d, J=8.0 Hz, 2H), 8.10 (bs, IH), 7.75 (dd, J=2.4, 8.8 Hz, IH), 7.70 (s, IH), 7.60 (d, J=8.0 Hz, 2H), 6.85 (d, J=8.8 Hz, IH), 3.80 (d, J=15.9 Hz, 2H), 2.60 (q, J=7.8 Hz, 2H), 1.95-1.00 (m, 14H).
Step G: Preparation of 4-{ [3-ethyl-4-(cyclohexylmethyl- oxy)phenvnmethylamino Ipyridine (23-8)
Figure imgf000109_0001
To a solution of 23 7 (290 mg, 0.86 mmol) in 5 mL of THF was added 1.7 mL (1.7 mmol) of LiAlH4 OM in THF) and the resulting solution was heated at 50°C for 2 h, cooled to 0°C and quenched with 0.07 mL of water, 0.07 mL of 15% NaOH and 0.2 mL of water. The precipitate was filtered, concentrated and purified by column chromatography (94:6:0.6 CHCI3 / IPA / NH4OH) to afford product 23-8. iH NMR (CDC13) δ 8.18 (d, J=8.1 Hz, 2H), 7.10 (d, J=7.5 Hz, IH), 7.07 (s, IH), 6.77 (d, J=7.5 Hz, IH), 6.41 (d, J=8.1 Hz, 2H), 4.39 (bs, IH), 4.24 (d, J=15.9 Hz, 2H), 3.74 (d, J=5.1 Hz, 2H), 2.60 (q, J=7.8 Hz,
2H), 2.00-1.00 (m, 14H); Analysis calculated for C21 H28N2O C, 77.72; H, 8.71 , N, 8.63 Found: C, 77.53; H, 8.62; N, 8.56
The compounds shown in the table below are exemplary compounds of the present invention. The range of Ki values associated with the specifically listed compounds is represented as follows:
+ <0.1 μM
++ >0.1 μM and <1.0 μM
+++ >1.0 μM and <10.0 μM
++++ >10.0 μM TABLE 3
Figure imgf000110_0001
H -CH2CH3 H H 0.64 116-9C o 00
Figure imgf000110_0002
Figure imgf000110_0004
Figure imgf000110_0003
R Rl R2 R3 R4 Ki(th)μM mp
H CH2CH(CH3)2 H H 1.5 103-6°
Figure imgf000111_0001
Figure imgf000111_0002
R Rl R2 R3 R4 Ki(th)μM mp
Figure imgf000112_0001
Figure imgf000112_0002
Figure imgf000112_0004
Figure imgf000112_0003
R Rl R2 R3 R4 Ki(th)μM mp
Figure imgf000113_0001
ase)
Figure imgf000113_0002
ase)
Figure imgf000113_0003
TABLE 4
Figure imgf000114_0001
W Y Ki (thr)
Figure imgf000114_0002
CONCH3 H H H ++++
Figure imgf000114_0003
Figure imgf000114_0004
+++
Figure imgf000114_0006
++++
Figure imgf000114_0005
R W Y Ki (thr)
Figure imgf000115_0001
i-butyl n-Pr H H H +++ n-Pr H H H +++
Figure imgf000115_0002
EXAMPLE 24
Preparation of N-((4-benzyloxy)phenylsulfonyl)-N'-aminomethyl- iminopiperazine (24-5)
Figure imgf000116_0001
Figure imgf000116_0002
Step A: Preparation of 4-benzyloxyphenylsulfonyl chloride (24-2)
Figure imgf000117_0001
To a 0°C solution of sulfonyl chloride (1.9 mL, 23.8 mmol) in 2 mL of DMF was added 4.0 g (21.7 mmol) of benzyl phenyl ether (24-1 ). The resulting solution was then heated at 100°C for 2h. The reaction mixture was then cooled and poured onto crushed ice. The aqueous layer was extracted with CH2CI2 (x3). The combined organic extracts were dried (Na2S04) and concentrated. Column chromatography (95 : 5 Hexane / EtOAc) and trituration (hexane) of the pure fractions afforded 24-2 as a pink solid. iH NMR (CDCI3) δ 8.00 (d, J=7.8 Hz, 2H), 7.45 (m, 5H), 7.10 (d, J=7.8 Hz, 2H), 5.15 (s, 2H).
Step B: Preparation of N-((4-benzyloxy)phenylsulfonyI)-N'-t- Butyloxycarbonylpiperazine (24-3) -
Figure imgf000117_0002
To a 0°C solution of 24^2 (250 mg, 1.0 mmol) in 3 mL of CH2CI2 was added 0.15 mL (1.1 mmol) of Et3N followed by 204 mg (1.1 mmol) of BOC piperazine. The resulting solution was allowed to stir to rt over 72h. The reaction mixture was diluted with CH2CI2 and washed with sat'd NaHCθ3 (3 x 5 mL). The organic phase was dried (Na2Sθ4) and concentrated to afford product 24-3 which was used directly without any purification. lH NMR (CDCI3) δ 7.70 (d, J=7.8 Hz, 2H), 7.40 (m, 5H), 7.10 (d, J=7.8 Hz, 2H), 5.18 (s, 2H), 3.58 (t, J=7 Hz, 4H), 2.95 (t, J=7 Hz, 4H), 1.40 (s, 9H).
Step C: Preparation of N-((4-benzyloxy)phenylsuIfonyl)- piperazine (24-4)
Figure imgf000118_0001
A -25°C solution of crude 2 ^3 (390 mg, 0.94 mmol) in 10 mL of EtOAc was treated with HCI gas for 5 min and then stirred for 2h at this temperature. Excess HCI was displaced from the solution by bubbling N2 through the reaction mixture. The resulting solution was concentrated to give the amine hydrochloride as a white solid which was triturated (EtOAc) to give product 24-4. iH NMR (CDCI3) δ 7.80 (d, J=7.8 Hz, 2H), 7.40 (m, 5H), 7.20 (d, J=7.8 Hz, 2H), 5.10 (s, 2H), 3,30 (m, 4H), 3.20 (m, 4H).
Step D: Preparation of N-((4-benzyloxy)phenylsulfonyI)-N' aminomethyliminopiperazine (24-5)
Figure imgf000118_0002
To a -25°C solution of 244 (300 mg, 0.90 mmol) in 10 mL of DMF and 0.25 mL (1.79 mmol) of Et3N was added 11 1 mg (0.895 mmol) of guanidine sulfonic acid. The resulting solution was allowed to stir to RT over 16h. The reaction mixture was concentrated and subjected to preparative HPLC to afford product 24-5 as its TFA salt. *H NMR (CD3OD) δ 7.80 (d, J=7.8 Hz, 2H), 7.40 (m, 5H), 7.20 (d, J=7.8 Hz, 2H), 5.20 (s, 2H), 3,60 (m, 4H), 3.05 (m, 4H); MS (FAB) =
375;
Analysis calculated for C 18H22N4O3S • 0.4 H2O • CF3COOH
C, 48.46; H, 4.84, N, 11.30 Found: C, 48.76; H, 4.69; N, 10.94
EXAMPLE 25
Preparation of N-((4-cyclohexylmemyloxy)-3-ethyl-phenylsulfonyl)-
N'-aminomethy liminopiperazine (25-1 )
25-1 was synthesized in the same manner as 24-5 by substituting 4-cyclohexylmethyloxy-3-ethylbenzene for 4- benzyloxybenzene in Step A, Example 24 .
The compounds shown in the table below are exemplary compounds of the present invention. The range of Ki values associated with the specifically listed compounds is represented as follows:
+ <0.1 μM
>0.1 μM and <1.0 μM
>1.0 μM and <10.0 μM ++++ >10.0 μM
Figure imgf000120_0001
TABLE 5
RI Ki(thr) μM mp
Figure imgf000120_0002
-CH2CH3 ++ 237-9°
Figure imgf000120_0003
EXAMPLE 26
Preparation of 4-{ [4-(Phenylmemyloxy)phenyl]methyl}benzamidine hydrochloride (26-6)
Step A: Preparation of 4-[(4-Methoxyphenyl)hydroxy- methyllbenzonitrile (26-2)
Figure imgf000121_0001
26-1 26-2
To a suspension of 4-(4-methoxybenzoyl)benzonitrile 26-1 (7. Med. Chem.. 1991, 34, 2768-2778) (0.783 g, 3.3 mmol) in ethanol (35 ml) under nitrogen cooled in an ice-bath was added sodium borohydride (0.250g, 6.6 mmol). The mixture was stirred 4h with ice- bath cooling. To the resulting solution was added saturated ammonium chloride solution (35 ml). The mixture was partially evaporated under reduced pressure, and the resulting aqueous mixture was extracted with ethyl acetate (2 x 100 ml). The combined organic fractions were washed with brine (50 ml), dried (sodium sulfate), and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with ethyl acetate/hexane (1 :6 increasing to 1 :3), to give product 26-2 as an oil. NMR δ H(CDCl3) 7.61 (2H, d, 7=8 Hz), 7.50 (2H, d, 7=8 Hz), 7.23 (2H, d, 7=9 Hz), 6.87 (2H, dd, 7=9, 2 Hz), 5.82 (IH, d, 7=3 Hz), 3.79 (3H, s), 2.37 (lH, bs); IR 2227 cm- 1. Step B: Preparation of 4-[(4-Methoxyphenyl)methyl]benzonitrile (26-3)
Figure imgf000122_0001
26-3
To a mixture of 26-2 (0.622 g, 2.6 mmol) and sodium iodide (1.56 g, 10.4 mmol) in acetonitrile (7 ml) at ambient temperature in a 3-necked round bottom flask equipped with a nitrogen inlet and rubber septum was added dichlorodimethylsilane (0.63 ml, 5.2 mmol) via syringe. The resulting mixture was stirred 60 min. Saturated sodium bicarbonate solution (30 ml) was added and the mixture was extracted with ethyl acetate (2 x 90 ml). The combined organic fractions were washed with 10% sodium thiosulfate solution (30 ml), brine (30 ml), dried (sodium sulfate), and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with ethyl acetate/hexane (1 :6 increasing to 1 :5), to give product 26-3 as a white solid, mp: 41.5- 43.5°C. dH(CDCl3) 7.56 (2H, d, 7= 8 Hz), 7.27 (2H, d, 7= 8 Hz), 7.07 (2H, d, 7= 9 Hz), 6.85 (2H, d, 7= 9 Hz), 3.97 (2H, s), 3.79 (3H, s). IR 2224 cm-l .
Step C: Preparation of 4-[(4-Hydroxyphenyl)methyIjbenzonitrile
(26-4)
Figure imgf000122_0002
To a solution of 26-3 (0.391 g, 1.75 mmol) in methylene chloride (6 ml) cooled in an ice-bath in a 3 -necked round bottom flask equipped with a nitrogen inlet and rubber septum was added 1.0M boron tribromide in methylene chloride (3.9 ml, 3.9 mmol) via syringe. The resulting mixture was stirred 18h while warming to ambient temperature. Water (7 ml) was added and the mixture was extracted with ether (35 ml). The organic fraction was washed with brine (10 ml), dried (sodium sulfate), and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with ethyl acetate/hexane (1:5 increasing to 1:3), to give product 26-4 as a white solid, mp: 163- 164°C. δ H(CDC13) 7.56 (2H, d, 7= 8 Hz), 7.26 (2H, d, 7= 8 Hz), 7.02 (2H, d, 7= 8 Hz), 6.78 (2H, d, 7= 8 Hz), 4.78 (IH, s), 3.96 (2H, s). IR 2230 cm-l.
Step D: Preparation of 4-{ [4-(Phenylmethyloxy)phenyl]- methyllbenzonitrile (26-5)
Figure imgf000123_0001
26-4
Figure imgf000123_0002
To a mixture of 26-4 (0.105 g, 0.50 mmol) and cesium carbonate (0.326 g, 1.0 mmol) in dimethylformamide (1 ml) under nitrogen was added benzyl bromide (0.071 ml, 0.60 mmol). The mixture was stirred 18h at ambient temperature. The resulting mixture was evaporated under reduced pressure. To the residue was added saturated sodium bicarbonate solution (15 ml), and the aqueous mixture was extracted with methylene chloride (2 x 30 ml). The organic fraction was washed with brine (10 ml), dried (sodium sulfate), and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with ethyl acetate/hexane (1 :6 increasing to 1 :5), to give a white solid. The solid was recrystallized from ethyl acetate/hexane to give product 26-5 as white crystals, mp: 1 10-11 1°C. δ H(CDC13) 7.56 (2H, d, 7=8 Hz), 7.32-7.44 (5H, m), 7.27 (2H, d, 7=8 Hz), 7.07 (2H, d, 7=9 Hz), 6.92 (2H, d, 7=9 Hz), 5.04 (2H, s), 3.97 (2H, s); IR 2223 cm"1;
Analysis calculated for C21 H 17NO
C, 84.25; H, 5.72; N, 4.68
Found: C, 84.02; H, 5.66; N, 4.74
Step E: Preparation of 4-{ [4-(Phenylmethyloxy)phenyl]- methy 11 benzamidine hydrochloride (26-6)
Figure imgf000124_0001
To a solution of 26-5 (0.081 g, 0.27 mmol) in anhydrous ether (4 ml) at ambient temperature in a 3-necked round bottom flask equipped with a nitrogen inlet and rubber septum was added 1.0 M lithium bis(trimethysilyl)-amide in THF (0.30 ml, 0.30 mmol) via syringe. The resulting solution was stirred 18h at ambient temperature. To the solution was added ethanolic HCI (6M, 0.18 ml, 1.1 mmol, 4 equivalents). The mixture was stirred 4h and the resulting precipitate was filtered off to give a solid (0.094g). The solid was placed in saturated sodium bicarbonate solution (3 ml) and was extracted with ethyl acetate (5 x 10 ml). The combined organic fractions were washed with brine (10 ml), dried (sodium sulfate), and the solvent was evaporated under reduced pressure. The residue (0.017g) was suspended in ethanol (1 ml) and ethanolic HCI (6 M, 0.010 ml) was added. The mixture was stirred, diluted with ether (5 ml), and the resulting precipitate was collected. The precipitate was then stirred under water (1 ml) for lh. The resulting solid was collected and dried in vacuo to give product 26-6. as an off-white solid, mp: 234-236°C. δ H(DMSO-d6) 9.30 (2H, br s), 9.09 (2H, br s), 7.74 (2H, d, 7=8 Hz), 7.32-7.47 (7H, m), 7.17 (2H, d, 7=8 Hz), 6.95 (2H, d, 7=8 Hz), 5.06
(2H, s), 3.98 (2H, s).
Analysis calculated for C21 H2θN2θ«HCl-0.65 H2O
C, 69.18; H, 6.17; N, 7.68 Found: C, 69.24; H, 5.93; N, 7.40
EXAMPLE 27
Preparation of 4-{ [4-(Cyclohexylmemyloxy)phenyl]methyl }- benzamidine hydrochloride (27-1)
Figure imgf000125_0001
26-4
Figure imgf000125_0002
Step A: Preparation of 4- { [4-(Cyclohexylmethyloxy)phenyl]- ethyUbenzonitrile (27-1)
Employing the procedure substantially as described above, but substituting cyclohexylmethyl bromide for the benzyl bromide, the desired compound 27^1 was prepared: mp: 104-106°C; iH NMR (CDC13) δ 7.56 (2H, d, 7=8 Hz), 7.26 (2H, d, 7=8 Hz), 7.05 (2H, d, 7=8 Hz), 6.83 (2H, d, 7=8 Hz), 3.96 (2H, s), 3.72 (2H, d, 7= 6 Hz), 1.68-1.87 (6H, m), 1.17-1.38 (3H, m), 0.97-1.08 (2H, m); IR 2223 cm-1.
Step B: Preparation of 4- { [4-(Cyclohexylmethyloxy)phenyl]- methvDbenzamidine hydrochloride (27-3)
Figure imgf000126_0001
Into a suspension of 27- 1 (0.101 g, 0.33 mmol) in ethanol (3 ml) under nitrogen cooled in an ice-bath was bubbled hydrogen chloride until the mixture was saturated. The mixture was stirred 18h while warming to ambient temperature. To the resulting solution was added ether (12 ml) resulting in formation of a precipitate. The precipitate was collected and dried in vacuo to give ethyl 4-{ [4- (cyclohexylmethyloxy)phenyl] -methyl jbenzimidate hydrochloride 27-2 as a white solid. NMR δ H(DMSO-d6) 1 1.0-11.8 (2H, br s), 7.98 (2H, d, 7=8 Hz), 7.48 (2H, d, 7=8 Hz), 7.13 (2H, d, 7=8 Hz), 6.85 (2H, d, 7=8 Hz), 4.57 (2H, q, 7=7 Hz), 3.99 (2H, s), 3.72 (2H, d, 7=6 Hz), 1.68-1.80 (6H, m), 1.47 (3H, t, 7=7 Hz), 1.19-1.26 (3H, m), 0.99-1.06 (2H, m).
Into a suspension of 27-2 (0.101 g, 0.26 mmol) in ethanol (5 ml) cooled in an ice-bath was bubbled ammonia until the mixture was saturated. The mixture was stirred 18h while warming to ambient temperature. The resulting solution was evaporated to one-half volume under reduced pressure. Addition of ether (2 ml) resulted in formation of a precipitate. The precipitate was filtered off. The filtrate was evaporated under reduced pressure, and the residue was stirred under ether (5 ml). The resulting precipitate was collected and dried to give a solid. The solid (0.042 g) was suspended in ethanol (1 ml) and ethanolic HCI (6 M 0.025 ml) was added. The mixture was stirred, diluted with ether (10 ml), and the resulting precipitate was collected and dried in vacuo to give 27-3. as a white solid, mp: 257-258°C. δ H(DMSO-d6) 9.1 (4H, br s), 7.73 (2H, d, 7=8 Hz), 7.45 (2H, d, 7=8 Hz), 7.14 (2H, d, 7=8 Hz), 6.84 (2H, d, 7=8 Hz), 3.97 (2H, s), 3.72 (2H, d, 7=6 Hz), 1.63-1.80 (6H, m), 1.15-1.30 (3H, m), 0.95-1.10 (2H, m); Analysis calculated for C21 H26N2O-HC1-0.40 H2O
C, 68.89; H, 7.65; N, 7.68 Found: C, 68.84; H, 7.45; N, 7.75
126-
Figure imgf000128_0001
Figure imgf000129_0001
-CH2- -O- -CH3 0.102 249-250°
Figure imgf000129_0002
Figure imgf000129_0003
Figure imgf000129_0004
-CH3 0.020 197-200°
Figure imgf000129_0005
Figure imgf000129_0006
Prepa
Figure imgf000130_0001
Figure imgf000130_0002
Figure imgf000130_0003
Figure imgf000130_0004
Figure imgf000130_0005
Step A: Preparation of methyl 4-(phenoxymethyl)benzoate (28-3)
In a round bottom flask under N2 was placed 28-1 (1.49 g, 15.9 mmol), CS2CO3 (5.2 g, 16 mmol), 2£ι2 (3.6 g, 15.7 mmol) in DMF (250 ml) and the suspension stirred at room temperature. After 18 h, the mixture was poured into saturated Na2C03 and extracted with EtOAc (3x). The organic extracts were dried, filtered and conc'd to dryness to yield 28-3.
!H NMR (CDC13) δ 3.85 (3H, s), 5.05 (2H, s), 6.9 (3H, m), 7.2 (2H, d), 7.45 (2H, d), 8.0 (2H, d).
Step B: Preparation of 4-(phenoxymethyl)benzoic acid (28-4)
Under N2, a mixture of 28-3 (4.1 g, 15.9 mmol) in EtOH (100 ml) and 5 N NaOH (100 ml) was stirred at room temperature. After 18 h, the reaction was heated at 80°C for 1/2 h, cooled to room temperature and then acidified with 6 N HCI. The mixture was extracted with EtOAc (3x) and the combined organic layer was washed with brine, dried, filtered and concentrated to dryness. The residue was triturated with Et2θ to yield 28-4. iH NMR (d6-DMSO) δ 5.5 (2H, s), 7.35 (3H, m), 7.6 (H, m), 7.9 (2H, d), 8.35 (2H, d).
Step C: Preparation of N-( 4-(phenoxymethyl)benzcarbox- amido)pyridine (28-5)
To a suspension of 28^4 (2.5 g, 11 mmol) in CH2CI2 (40 ml) with 4 drops of DMF was added with stirring under N2 at room temperature oxalyl chloride (1.7 g, 14 mmol). After 2h, the solution was concentrated to dryness, flushed with CHCI3 and then dissolved in CHCI3 (30 ml). This solution was then added dropwise to a suspension of 4-aminopyridine (3.1 g, 33 mmol) in CHCI3 (50 ml). After stirring at room temperature ovemight, a sat'd solution of Na2C03 was added and separated. The aqueous was further extracted with EtOAc (3x). The combined extracts were backwashed with H2O, dried, filtered and concentrated to dryness. The residue was chromatographed on a Still column (60 mm) and the product eluted with 10% CH3OH/CHCI3 to yield 2&ά; mp: 195- 197°C (EtOH-CH3θH); iH NMR (d6-DMSO) δ 5.2 (2H, s), 6.95 (IH, t), 7.03 (2H, d), 7.3 (2H, t), 7.62 (2H, d), 7.79 (2H, d), 7.99 (2H, d), 8.48 (2H, d). Analysis calculated for C 19H 16N2O2
C 74.98, H 5.30, N 9.21 Found: C 74.63, H 5.32, N 9.17
Step D: Preparation of N-( 4-phenoxymethylbenzyl)amino- pyridine (28-6)
Under N2, a solution of LAH 1.0 M in hexane (10 ml, 10 mmol) was added dropwise to a suspension of 28-5 (1.75 g, 5.8 mmol) in THF (200 ml). After heating at 60° ovemight with stirring, a sat'd solution of Na2Sθ4 was added until a white suspension was formed. The mixture was poured through super eel and washed with EtOAc. The organic layer was washed with water and the aqueous layer further extracted with EtOAc (2x). The combined organic extracts were dried, filtered and concentrated to dryness. The residue was chromatographed on a Still column (40 mm) and the product eluted with 10% CH3OH- CHCI3. The hydrochloride salt was prepared from EtOH-HCl and the product crystallized from EtOH to yield 28^5; mp: 213-215°C. The compound analyzed for C 19H 1 N2θ»HCl ; *H NMR (d6-DMSO) δ 4.55 (2H, d), 5.05 (2H, s), 6.95 (5H, m), 7.25
(2H, t), 7.4 (4H, q), 8.15 (2H, bd).
Analysis calculated for C, 69.82; H, 5.86; N 8.57
C, 69.82; H, 5.86; N, 8.57 Found: C, 69.73; H, 5.88; N, 8.58
The compounds shown in the table below are exemplary compounds of the present invention. The range of Ki values associated with the specifically listed compounds is represented as follows:
+ <0.1 μM
-H- >0.1 μM and < 1.0 μM
+++ >1.0 μM and <10.0 μM ++-H- >10.0 μM TABLE 7
Figure imgf000133_0001
R RI Ki(thr) p μM
Figure imgf000133_0002
EXAMPLE 29
Preparation of 4-(2-(3-cyclohexylmethyIoxy-phenyl)ethyl)amino- pyridine (29-6
Figure imgf000133_0003
Step A: Preparation of ethyl 3-hydroxy-phenylacetate (29-2)
Figure imgf000134_0001
Sulfuric acid (0.018 mL, 0.329 mmol, 0.1 equiv) was added to a solution of 3-hydroxy-phenylacetic acid (29-1 ) (500 mg, 3.29 mmol, 1 equiv) in ethanol (10 mL) at 23°C. The reaction mixture was heated at reflux for 1.5 h. The solution was cooled to 23°C, then was concentrated. The residue was diluted with ethyl acetate, and the resulting solution was washed with water (2 x 20 mL). The organic layer was dried over magnesium sulfate and was concentrated to afford the product as a colorless oil 29-2 which was used without further purification. iH NMR (400 MHz, CDCI3), δ: 7.17 (t, IH, 7 = = 7.88 Hz, ArH [meta to OH]), 6.83 (d, IH, 7 = = 7.51 Hz, ArH [ortho to OH]), 6.78 (s, I H, ArH [ortho to OH]), 6.74 (d, IH, 7 = = 8.05 Hz, ArH [para to OH]), 5.90 (br s, IH, ArOH), 4.17 (q, 2H, 7 = = 7.15 Hz, CO2CH2CH3), 3.57 (s, 2H, CH2CO2CH2CH3), 1.26 (t, 3H, 7 = = 7.14 Hz, CO2CH2CH3).
Step B: Preparation of ethyl 3-cyclohexylmethyloxy-phenylacetate (29-3)
Figure imgf000134_0002
Cyclohexylmethyl bromide (0.459 mL, 3.29 mmol, 1 equiv) was added to a suspension of 29-2 (592 mg, 3.29 mmol, 1 equiv) and cesium carbonate (1.07 g, 3.29 mmol, 1 equiv) in N, N- dimethylformamide (6 mL) at 23°C. The reaction mixture was heated to 70°C and was stirred at that temperature for 3h. The solution was cooled to 23°C and was concentrated. The residue was diluted with ethyl acetate, and the resulting solution was washed with an aqueous saturated ammonium chloride solution (2 x 20 mL). Organic layer was dried over magnesium sulfate and was concentrated. The resulting oil was purified by flash column chromatography (5% ethyl acetate in hexane) to afford the product as a colorless oil 29-3 as well as recovered ethyl 3-hydroxy-phenylacetate. iH NMR (400 MHz, CDCI3), δ: 7.21 (t, IH, 7 = 7.69 Hz, ArH [meta to OCH2Cy]), 6.81 (m, 2H, ArH [ortho and para to OCH2Cy]), 6.83 (s, IH, ArH [ortho to the OCH2Cy]), 4.15 (q, 2H, 7 = 7.14 Hz, CO2CH2CH3), 3.74 (d, 2H, 7=6.40 Hz, OCH2Cy), 3.57 (s, 2H, CH2CO2CH2CH3), 1.86 (d, 2H, 7= 12.6 Hz, CyH), 1.74 (m, 4H, CyH), 1.24 (m, 3H, CyH), 1.25 (t, 3H, 7=7.14 Hz, CO2CH2CH3), 1.05 (m, 2H, CyH); TLC (10% EtOAc-hexane), Rf = 0.50 (UV)
Step C: Preparation of 3-cyclohexylmethyloxy-phenylacetic acid (29-4) '
Figure imgf000135_0001
A solution of aqueous sodium hydroxide (IN, 14 mL, 14.0 mmol, 10 equiv) was added to a solution of ethyl 3-cyclohexyl- methyloxy-phenylacetate 29-3 (384 mg, 1.39 mmol, 1 equiv) in a mixture of t-butanol (8 mL) and water (4 mL) at 23 °C. The reaction mixture was heated at reflux for 2h. The solution was cooled to 23°C and was diluted with ethyl acetate (50 mL). The organic layer was washed with an aqueous 10% potassium hydrogen sulfate solution (2 x 25 mL), then was dried over magnesium sulfate and was concentrated to afford the product 29-4 as a white solid, which was used without further purification. iH NMR (400 MHz, CD3OD), δ: 7.19 (t, IH, 7= 7.88 Hz, ArH [meta to OCH2Cy]), 6.83 (s, IH, ArH [ortho to OCH2Cy]), 6.79 (m, 2H, ArH [ortho and para to OCH2Cy]), 3.75 (d, 2H, 7=6.04 Hz, OCH2Cy), 3.55 (s, 2H, CH2CO2H), 1.87 (d, 2H, 7=12.5 Hz, CyH), 1.74 (m, 4H, CyH), 1.29 (m, 3H, CyH), 1.10 (m, 2H, CyH).
Step D: Preparation of N-4'-pyridyl-(3-cyclohexylmethyl- oxy)phenylacetamide (29-5)
Figure imgf000136_0001
Oxalyl chloride (0.158 mL, 1.81 mmol, 3 equiv) and a catalytic amount of N, N-dimethylformamide (2 mL) were added consecutively to a solution of 29-4 (150 mg, 0.604 mmol, 1 equiv) in dichloromethane (2 mL) at 23°C. Once gas evolution ceased (approximately 2 min following the addition of the N, N- dimethylformamide), the volatiles were removed in vacuo. The residue was dissolved in dichloromethane (2 mL), and the resulting solution was transferred via cannula to a suspension of 4-aminopyridine (284 mg, 3.02 mmol, 5 equiv) and triethylamine (0.673 mL, 4.83 mmol, 8 equiv) in dichloromethane (2 mL) at 23°C. The reaction mixture was stirred for 2.5 h at 23°C and then was concentrated in vacuo. The residue was diluted with ethyl acetate (50 mL), and the resulting solution was washed with an aqueous saturated ammonium chloride solution (2 x 20 mL). The organic layer was dried over magnesium sulfate and was concentrated. The residue was purified by flash column chromatography (100% ethyl acetate) to afford 29-5 as a yellow oil (36 mg, 18.4 %). iH NMR (400 MHz, CDCI3 ), δ: 8.46 (dd, 2H, 7=4.86, 1.56 Hz, PyH), 7.36 (dd, 2H, 7 = 4.85, 1.56 Hz, PyH), 7.32 (t, IH, 7=7.88 Hz, ArH [meta to OCH2Cy]), 7.17 (s, IH, Amide H), 6.88 (m, 2H, ArH [ortho to OCH2Cy]), 6.84 (d, IH, 7=1.83 Hz, ArH [para to OCH2Cy]), 3.76 (d, 2H, 7=6.23 Hz, OCH2Cy), 3.72 (s, 2H, CH2-amide), 1.86 (d, 2H, 7=13.18 Hz, CyH), 1.76 (m, 4H, CyH), 1.29 (m, 3H, CyH), 1.04 (m, 2H, CyH). TLC (EtOAc), Rf. = 0.20 (UV).
Step E: Preparation of 4-(2-(3-cyclohexylmethyIoxy- phenvDethyDaminopyridine (29-6)
Figure imgf000137_0001
A solution of lithium aluminum hydride in tetrahydrofuran (1.0 M, 0.308 ml, 0.308 mmol, 4 equiv) was added to a solution of 29-5 (25 mg, 0.077 mmol, 1 equiv) in tetrahydrofuran (2 mL) at 0°C. The reaction mixture was heated to 50°C and was held at that temperature for 2 h. The mixture was cooled to 0°C, and excess lithium aluminum hydride was quenched by the consecutive addition of water (12 μl), aqueous 15% sodium hydroxide solution (12 μl), and water (36 μl). The resulting aluminum salts were removed by filtration. The filtrate was concentrated, and the residue was purified by flash column chromatography (1 % methanol in chloroform saturated with ammonia) to afford the product 29-6 as a pale yellow solid (mp: = 81-83°C). iH NMR (400 MHz, CDCI3 ), δ: 8.20 (dd, 2H, 7=4.94, 1.47 Hz, PyH), 7.23 (t, IH, 7=7.84 Hz, ArH [meta to OCH2Cy]), 6.78 (m, 3H, ArH [ortho and para to OCH2Cy]), 6.43 (dd, 2H, 7=4.85, 1.56 Hz, PyH), 4.15 (s, IH, NH), 3.74 (d, 2H, 7=6.22 Hz, OCH2Cy), 3.44 (q, 2H, 7=6.87 Hz, CH2NH), 2.89 (t, 2H, 7=6.87 Hz, CH2CH2NH), 1.87 (d, 2H, 7=13.37 Hz, CyH), 1.77 (m, 4H, CyH), 1.27 (m, 3H, CyH), 1.06 (m, 2H, CyH); TLC (1 % MeOH-CHCl3 sat'd with NH3), Rf. = 0.27 (UV)
In vitro assay for determining proteinase inhibition
Assays of human a-thrombin and human trypsin were performed at 25°C in 0.05 M TRIS buffer pH 7.4, 0.15 M NaCl, 0.1 % PEG. Trypsin assays also contained 1 mM CaCl2-
In assays wherein rates of hydrolysis of a p-nitroanilide (pna) substrate were determined, a Thermomax 96-well plate reader was used to measure (at 405 nm) the time dependent appearance of p- nitroaniline. sar-PR-pna (sarcosine-Pro-Arg-p-nitroanilide) was used to assay human a-thrombin (Km=125 μM) and human trypsin (Km=59 μM). /7-Nitroanilide substrate concentration was determined from measurements of absorbance at 342 nm using an extinction coefficient of 8270 cm-lM"1.
In certain studies with potent inhibitors (Ki < 10 nM) where the degree of inhibition of thrombin was high, a more sensitive activity assay was employed. In this assay the rate of thrombin catalyzed hydrolysis of the fluorogenic substrate Z-GPR-afc (Cbz-Gly- Pro-Arg-7-amino-4-trifluoromethyl coumarin) (Km=27 μM) was determined from the increase in fluorescence at 500 nm (excitation at 400 nm) associated with production of 7-amino-4-trifluoromethyl coumarin. Concentrations of stock solutions of Z-GPR-afc were determined from measurements of absorbance at 380 nm of the 7- amino-4-trifluoromethylcoumarin produced upon complete hydrolysis of an aliquot of the stock solution by thrombin. Activity assays were performed by diluting a stock solution of substrate at least tenfold to a final concentration 0.5 Km into a solution containing enzyme or enzyme equilibrated with inhibitor. Times required to achieve equilibration between enzyme and inhibitor were determined in control experiments. Initial velocities of product formation in the absence (Vo) or presence of inhibitor (Vi) were measured. Assuming competitive inhibition, and that unity is negligible compared Km/[S], [I]/e, and [I]/e (where [S], [I], and e respectively represent the total concentrations, of substrate, inhibitor and enzyme), the equilibrium constant (Ki) for dissociation of the inhibitor from the enzyme can be obtained from the dependence of Vo/Vi on [I] shown in equation 1.
Vo/Vi = 1 + [I]/Ki (1)
The activities shown by this assay indicate that the compounds of the invention are therapeutically useful for treating various conditions in patients suffering from unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, and reocclusion or restenosis of recanahzed vessels.
Thrombin Inhibitors - Therapeutic Uses
Anticoagulant therapy is indicated for the treatment and prevention of a variety of thrombotic conditions, particularly coronary artery and cerebrovascular disease. Those experienced in this field are readily aware of the circumstances requiring anticoagulant therapy. The term "patient" used herein is taken to mean mammals such as primates, including humans, sheep, horses, cattle, pigs, dogs, cats, rats, and mice.
Thrombin inhibition is useful not only in the anticoagulant therapy of individuals having thrombotic conditions, but is useful whenever inhibition of blood coagulation is required such as to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage. Thus, thrombin inhibitors can be added to or contacted with any medium containing or suspected of containing thrombin and in which it is desired that blood coagulation be inhibited, e.g., when contacting the mammal's blood with material selected from the group consisting of vascular grafts, stents, orthopedic prothesis, cardiac prosthesis, and extracorporeal circulation systems
The thrombin inhibitors of the invention can be administered in such oral forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixers, tinctures, suspensions, syrups, and emulsions. Likewise, they may be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an anti -aggregation agent. For treating ocular build up of fibrin, the compounds may be administered intraocularly or topically as well as orally or parenterally.
The thrombin inhibitors can be administered in the form of a depot injection or implant preparation which may be formulated in such a manner as to permit a sustained release of the active ingredient. The active ingredient can be compressed into pellets or small cylinders and implanted subcutaneously or intramuscularly as depot injections or implants. Implants may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or . other polymers manufactured by the Dow-Coming Corporation.
The thrombin inhibitors can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
The thrombin inhibitors may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The thrombin inhibitors may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinlypyrrolidone, pyran copolymer, polyhydroxy-propyl- methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the thrombin inhibitors may be coupled to a class of biodegradable polymers useful in achieving controlled release of a dmg, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
The dosage regimen utilizing the thrombin inhibitors is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the dmg required to prevent, counter, or arrest the progress of the condition.
Oral dosages of the thrombin inhibitors, when used for the indicated effects, will range between about 0.1 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day and preferably 1.0- 100 mg/kg/day and most preferably 1-20 mg/kg/day. Intravenously, the most preferred doses will range from about 0.01 to about 10 mg/kg/minute during a constant rate infusion. Advantageously, the thrombin inhibitors may be administered in divided doses of two, three, or four times daily. Furthermore, they can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, or course, be continuous rather than intermittent throughout the dosage regime. For example, oral tablets can be prepared which contain an amount of active compound of between 100 and 500 mg, typically between 200 and 250 mg. Typically, a patient in need of thrombin inhibitor compound, depending on weight and metabolism of the patient, would be administered between about 100 and 1000 mg active compound per day. For a patient requiring 1000 mg per day, two tablets containing 250 mg of active compound can be administered in the morning and two tablets containing 250 mg of active compound can again be administered in the evening. For a patient requiring 500 mg per day, one tablet containing 250 mg of active compound can be administered in the morning and one tablet containing 250 mg of active compound can again be administered in the evening.
The thrombin inhibitors are typically administered as active ingredients in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixers, symps and the like, and consistent with convention pharmaceutical practices.
For instance, for oral administration in the form of a tablet or capsule, the active dmg component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral dmg components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta- lactose, com-sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch methyl cellulose, agar, bentonite, xanthan gum and the like.
The thrombin inhibitors can also be co-administered with suitable anti-coagulation agents or thrombolytic agents such as plasminogen activators or streptokinase to achieve synergistic effects in the treatment of various ascular pathologies. For example, thrombin inhibitors enhance the efficiency of tissue plasminogen activator- mediated thrombolytic reperfusion. Thrombin inhibitors may be administered first following thrombus formation, and tissue plasminogen activator or other plasminogen activator is administered thereafter. They may also be combined with heparin, aspirin, or warfarin.
EXAMPLE 10
Tablet Preparation
Tablets containing 25.0, 50.0, and 100.0 mg., respectively, of the following active compound is prepared as illustrated below:
4-amino- 1 -(4-( 1 , 1 -diphenylmethoxy)benzylpyridinium bromide
TABLE FOR DOSES CONTAINING FROM 25-lOOMG OF THE ACTIVE COMPOUND
Amount-mg
Active Compound 25.0 50.0 100.0
Microcrystalline cellulose 37.25 100.0 200.0
Modified food com starch 37.25 4.25 8.5
Magnesium stearate 0.50 0.75 1.5 All of the active compound, cellulose, and a portion of the com starch are mixed and granulated to 10% com starch paste. The resulting granulation is sieved, dried and blended with the remainder of the com starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 25.0, 50.0, and 100.0 mg, respectively, of active ingredient per tablet.

Claims

WHAT IS CLAIMED IS:
1. A compounds having the following stmcture:
Figure imgf000145_0001
I
and pharmaceutically acceptable salts thereof wherein
X is
-N(R4)-,
-0-,
-S-,
-S02-,
-SO-,
-OCH2(CH2)n aryl-, or
-OCH2(CH2)n C3-8cycloalkyl-, wherein n is 1 or 2;
J is
-(CH2)πr,
-(CH2)mNH-,
-S02NH-,
-S02(CH2)m-, -NHS02-, -S02-, or -(CH2)mS02-, wherein m is 1 or 2;
Rl, R2, and R4 are independently selected from hydrogen, aryl, -C02R5, aryl Cl-4 alkyl, diaryl Cl-4 alkyl, dicyclo C3-8 alkyl Cl-4 alkyl, cyclo C3-8 alkyl Cl-4 alkyl,
Figure imgf000146_0001
and R6 are independently hydrogen or Cl-4 alkyl, substituted aryl with one or two substituents selected from
Cl-4 alkyl,
Cl-4 alkoxy,
/R5 CONχ
R , wherein R^ and R6 are independently hydrogen or Cι_4 alkyl, aryloxy, cyclo C3-8 alkoxy, methylenedioxy, halogen, or hydroxy, heteroaryl with one or two heteroatoms selected from N,
O, and S, cyclo C3-7 alkyl unsubstituted or substituted with one or more of Cl-4 alkyl, Cl-4 alkoxy, benzyl, cyclohexylmethyl or aryl, a C4-IO carbocyclic or bicyclic ring, or
R 1 and R2 along with the carbon to which they attach form a cyclo C3-
7 alkyl ring;
R3 is hydrogen,
Cl-4 alkyl,
Cl-4 alkenyl, Cl-4 alkoxy,
-NHR7 wherein R? is hydrogen or Cl-4 alkyl, or
-NHS02CH2aryl;
A is selected from one of the following fragments
Figure imgf000147_0001
Figure imgf000147_0002
' whθrein B is N or CH-
2. A compound of claim 1 having the following stmcture:
Figure imgf000147_0003
and pharmaceutically acceptable salts thereof wherein
J is (CH2)m, (CH2)mNH, or Sθ2, where m is 1 or 2;
R 1 and R2 are independently selected from hydrogen, aryl, or cyclo C3-7 alkyl unsubstituted or substituted with one or more of Cl-4 alkyl, Cl-4 alkoxy, benzyl, cyclohexylmethyl or aryl; R3is hydrogen, Cl-4 alkyl, or Ci-4alkenyl;
A is selected from one of the following fragments
Figure imgf000148_0001
Figure imgf000148_0002
, wherein B is N or CH.
3. A compound of claim 2 having the following stmcture:
Figure imgf000148_0003
and pharmaceutically acceptable salts thereof wherein
JisCH2,CH2NH,orS02;
Ri and R2 are independently selected from hydrogen, aryl, or cyclohexyl; R3is hydrogen, -CH=CH2, or -CH2CH3; and
A is selected from one of the following fragments
Figure imgf000149_0001
4. A compound of Claim 3 which has the stmcture:
Figure imgf000149_0002
Figure imgf000149_0003
Figure imgf000149_0004
, and
Figure imgf000149_0005
Figure imgf000150_0001
and pharmaceutically acceptable salts thereof.
5. A composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.
6. A method for inhibiting thrombin in blood in a mammal comprising administering to the mammal a composition of Claim 5.
7. A method for inhibiting formation of blood platelet aggregates in blood in a mammal comprising administering to the mammal a composition of Claim 5.
8. A method for inhibiting formation of fibrin in blood in a mammal comprising administering to the mammal a composition of Claim 5.
9. A method for inhibiting thrombus formation in blood in a mammal comprising administering to the mammal a composition of Claim 5.
10. A method for inhibiting thrombin in stored blood comprising administering to the mammal a composition of Claim 5.
1 1. A method for inhibiting formation of blood platelet aggregates in stored blood comprising administering to the mammal a composition of Claim 5
12. A method for inhibiting formation of fibrin in stored blood comprising administering to the mammal a composition of Claim 5.
13. A method for inhibiting thrombus formation in stored blood comprising administering to the mammal a composition of Claim 5.
14. The use of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting thrombus formation, preventing thrombus formation, inhibiting thrombin, inhibiting formation of fibrin, and inhibiting formation of blood platelet aggregates, in a mammal.
PCT/US1997/015989 1996-09-13 1997-09-09 Thrombin inhibitors WO1998010763A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002264037A CA2264037A1 (en) 1996-09-13 1997-09-09 Thrombin inhibitors
AU44117/97A AU725403B2 (en) 1996-09-13 1997-09-09 Thrombin inhibitors
EP97942415A EP0927035A4 (en) 1996-09-13 1997-09-09 Thrombin inhibitors
JP10513809A JP2001500864A (en) 1996-09-13 1997-09-09 Thrombin inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2603396P 1996-09-13 1996-09-13
US60/026,033 1996-09-13
GB9624278.9 1996-11-22
GBGB9624278.9A GB9624278D0 (en) 1996-11-22 1996-11-22 Thrombin inhibitors

Publications (1)

Publication Number Publication Date
WO1998010763A1 true WO1998010763A1 (en) 1998-03-19

Family

ID=26310456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/015989 WO1998010763A1 (en) 1996-09-13 1997-09-09 Thrombin inhibitors

Country Status (5)

Country Link
EP (1) EP0927035A4 (en)
JP (1) JP2001500864A (en)
AU (1) AU725403B2 (en)
CA (1) CA2264037A1 (en)
WO (1) WO1998010763A1 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133297A (en) * 1997-09-30 2000-10-17 Merck & Co., Inc. Thrombin inhibitors
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6624180B2 (en) 2000-11-20 2003-09-23 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6686484B2 (en) 2000-04-17 2004-02-03 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
US6693121B2 (en) 2000-04-05 2004-02-17 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6875791B2 (en) 2000-04-05 2005-04-05 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
US6969715B2 (en) 2001-10-03 2005-11-29 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
EP1601251A2 (en) * 2003-02-13 2005-12-07 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7071213B2 (en) 2001-11-14 2006-07-04 Schering Corporation Cannabinoid receptor ligands
US7105559B2 (en) 2001-10-03 2006-09-12 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
US7211816B2 (en) 2002-11-27 2007-05-01 International Business Machines Corporation Method for in-situ continuity check on an optical bus
US7217732B2 (en) 2002-06-19 2007-05-15 Schering Corporation Cannabinoid receptor agonists
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7642272B2 (en) 2003-03-20 2010-01-05 Schering Corporation Cannabinoid receptor ligands
US20130267707A1 (en) * 2010-12-30 2013-10-10 Zakrytoe Aktsionernoe Obschshestvo "Vertex" N,N+hu 1 +l SUBSTITUTED PIPERAZINES HAVING COMBINED ANTIAGGREGANT, ANTICOAGULANT AND VASODILATORY ACTIVITY, AND METHOD FOR PRODUCING SAME

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ530051A (en) * 2001-06-12 2006-12-22 Wellstat Therapeutics Corp Polycyclic oxy-aromatic acid derivatives for the treatment of metabolic disorders
CA2640976A1 (en) * 2006-02-01 2007-08-09 Merck & Co., Inc. Potassium channel inhibitors
US8067607B2 (en) * 2006-02-01 2011-11-29 Merck Sharp & Dohme Corp. Potassium channel inhibitors
WO2007089743A2 (en) * 2006-02-01 2007-08-09 Merck & Co., Inc. Potassium channel inhibitors
RU2353619C2 (en) * 2007-06-28 2009-04-27 Общество С Ограниченной Ответственностью "Бионика" Novel compounds possessing anticoagulant function, based on them pharmaceutical compositions for treatment of thrombotic conditions and plasma-substituting solution for correction of hypercoagulation disorders in hemodilution
RU2354647C2 (en) * 2007-06-28 2009-05-10 Общество С Ограниченной Ответственностью "Бионика" New compounds with thrombin inhibiting function, and based pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5518735A (en) * 1990-11-15 1996-05-21 Pentapharm Ag Meta-substituted phenylalanine derivatives
US5612363A (en) * 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283532A (en) * 1976-01-01 1977-07-12 Teijin Ltd Novel aromatic compounds
IL87181A (en) * 1987-08-07 1993-08-18 Sanofi Sa Aminoalkoxyphenyl derivatives, their preparation and pharmaceutical and veterinary compositions containing them
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
GB9214120D0 (en) * 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
TW257757B (en) * 1993-03-03 1995-09-21 Boehringer Mannheim Gmbh
US5530012A (en) * 1994-12-22 1996-06-25 Bristol-Myers Squibb Co. 3-alkoxybenzylpiperidine derivatives as melatonergic agents
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
ES2117950B1 (en) * 1996-08-02 1999-09-16 Univ Granada NEW COMPOUNDS THAT BLOCK THE BIOSYNTHESIS OF PHOSPHORYLCHOLINE AND ITS USE AS A SECOND MESSENGER IN CELL PROLIFERATION.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5518735A (en) * 1990-11-15 1996-05-21 Pentapharm Ag Meta-substituted phenylalanine derivatives
US5612363A (en) * 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. ENZYME INHIBITION, 1995, Vol. 9, MACK et al., "Design, Synthesis and Biological Activity of Novel Rigid Amidino-Phenylalanine Derivatives as Inhibitors of Thrombin", pages 73-86. *
See also references of EP0927035A4 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133297A (en) * 1997-09-30 2000-10-17 Merck & Co., Inc. Thrombin inhibitors
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6870056B1 (en) 1999-05-19 2005-03-22 Pharmacia Corporation Substitituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6852761B2 (en) 2000-03-13 2005-02-08 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
US6916847B2 (en) 2000-04-05 2005-07-12 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
US6693121B2 (en) 2000-04-05 2004-02-17 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
US6875791B2 (en) 2000-04-05 2005-04-05 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
US6686484B2 (en) 2000-04-17 2004-02-03 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
US6828338B2 (en) 2000-11-20 2004-12-07 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US6624180B2 (en) 2000-11-20 2003-09-23 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7718702B2 (en) 2001-02-08 2010-05-18 Schering Corporation Cannabinoid receptor ligands
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US6969715B2 (en) 2001-10-03 2005-11-29 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
US7105559B2 (en) 2001-10-03 2006-09-12 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
US7645774B2 (en) 2001-11-14 2010-01-12 Schering Corporation Cannabinoid receptor ligands
US7071213B2 (en) 2001-11-14 2006-07-04 Schering Corporation Cannabinoid receptor ligands
US7217732B2 (en) 2002-06-19 2007-05-15 Schering Corporation Cannabinoid receptor agonists
US7211816B2 (en) 2002-11-27 2007-05-01 International Business Machines Corporation Method for in-situ continuity check on an optical bus
EP1601251A4 (en) * 2003-02-13 2007-03-28 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
US7605181B2 (en) 2003-02-13 2009-10-20 Wellstat Therapeutics Orporation Method for the treatment of metabolic disorders
US7615575B2 (en) 2003-02-13 2009-11-10 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1601251A2 (en) * 2003-02-13 2005-12-07 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US7932290B2 (en) 2003-02-13 2011-04-26 Wellstat Biologics Corporation Method for the treatment of metabolic disorders
KR101106631B1 (en) * 2003-02-13 2012-01-20 웰스태트 테러퓨틱스 코포레이션 Compounds for the Treatment of Metabolic Disorders
US7642272B2 (en) 2003-03-20 2010-01-05 Schering Corporation Cannabinoid receptor ligands
US20130267707A1 (en) * 2010-12-30 2013-10-10 Zakrytoe Aktsionernoe Obschshestvo "Vertex" N,N+hu 1 +l SUBSTITUTED PIPERAZINES HAVING COMBINED ANTIAGGREGANT, ANTICOAGULANT AND VASODILATORY ACTIVITY, AND METHOD FOR PRODUCING SAME
US9249115B2 (en) * 2010-12-30 2016-02-02 Vertex Closed Joint Stock Company N,N1 substituted piperazines having combined antiaggregant, anticoagulant and vasodilatory activity, and method for producing same

Also Published As

Publication number Publication date
AU725403B2 (en) 2000-10-12
EP0927035A4 (en) 2002-11-13
AU4411797A (en) 1998-04-02
JP2001500864A (en) 2001-01-23
EP0927035A1 (en) 1999-07-07
CA2264037A1 (en) 1998-03-19

Similar Documents

Publication Publication Date Title
EP0927035A1 (en) Thrombin inhibitors
US5872138A (en) Thrombin inhibitors
US5792779A (en) Pyridinone thrombin inhibitors
US5744486A (en) Pyridinone thrombin inhibitors
JP3088016B2 (en) Heterocyclic compounds as platelet aggregation inhibitors
US5869487A (en) Pyrido 3,4-B!pyrazines for use as thrombin inhibitors
EP0934064B1 (en) Thrombin inhibitors
CA2493660A1 (en) Process for preparing quinolin antibiotic intermediates
AU2127497A (en) Pyridinone thrombin inhibitors
US4873253A (en) Phenylalanine derivative and proteinase inhibitor
CZ381397A3 (en) ARTYLSULFONYLAMINOBENZENE DERIVATIVES AND THEIR USE AS Xa FACTOR INHIBITORS
WO1999011267A1 (en) Pyrazinone thrombin inhibitors
AU5961398A (en) Thrombin inhibitors
JP2002512220A (en) Substituted benzamides, their preparation and use as inhibitors of cysteine protease
US6117888A (en) Thrombin inhibitors
US20030065176A1 (en) Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof
EP1456175A1 (en) Substituted heterocyclic carboxamides with antithrombotic activity
JP2000503010A (en) Amidino protease inhibitor
EP1539725A1 (en) 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors
US5798377A (en) Thrombin inhibitors
EP0598123A1 (en) Piperazine derivative and drug containing the same
SK10112000A3 (en) Matrix metalloprotease inhibitors
WO1997015190A1 (en) Thrombin inhibitors
US20030158218A1 (en) Thrombin inhibitors
US6011038A (en) Pyrazinone thrombin inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 11/98, UNDER INID (51) "IPC", REPLACE THE EXISTING SYMBOLS BY "A61K 31/44, 31/155, 31/495, C07C257/18, C07D213/72, 241/04"

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2264037

Country of ref document: CA

Ref country code: CA

Ref document number: 2264037

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 513809

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997942415

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997942415

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997942415

Country of ref document: EP